Advanced search
Publication Cover
Blood Pressure Volume 16, 2007 - Issue 3
Submit an article Journal homepage
2,731
Views
237
CrossRef citations to date
0
Altmetric
2007 Guidelines for the management of arterial hypertension

2007 ESH‐ESC Guidelines for the management of arterial hypertension

The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Pages 135-232 | Published online: 08 Jul 2009

References

  • Guidelines Sub‐Committee. 1993 Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905–918, GL
  • Guidelines Sub‐Committee. 1999 World Health Organization/International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183, GL
  • Guidelines Committee 2003. European Society of Hypertension‐European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053, GL
  • Top 10 papers published. The Scientist 2005; 19: 26, OS
  • ESH/ESC Hypertension Practice Guidelines Committee. Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens 2003; 21: 1779–1786, GL
  • Simoons M. L., van der Putten N., Wood D., Boersma E., Bassand J. P. The Cardiology Information System: the need for data standards for integration of systems for patient care, registries and guidelines for clinical practice. Eur Heart J 2002; 23: 1148–1152, GL
  • MacMahon S., Peto R., Cutler J., Collins R., Sorlie P., Neaton J., Abbott R., Godwin J., Dyer A., Stamler J. Blood pressure stroke coronary heart disease. Part 1 prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774, MA
  • Report of the Joint National Committee on Detection Evaluation. Treatment of High Blood Pressure: a cooperative study. JAMA 1977; 237: 255–261, GL
  • The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1980; 140: 1280–1285, GL
  • Collins R., Peto R., MacMahon S., Herbert P., Fieback N. H., Eberlein K. A., Godwin J., Qizilbash N., Taylor J. O., Hennekens C. H. Blood pressure stroke coronary heart disease. Part 2, short‐term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–839, MA
  • Prospective Studies Collaboration. Age‐specific relevance of usual blood pressure to vascular mortality: a meta‐analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913, MA
  • European cardiovascular disease statistics, British Heart Foundation 2000 www.dphpc.ox.ac/UKbhfhprg. RV,
  • Kannel W. B. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571–1576, OS
  • Levy D., Larson M. G., Vasan R. S., Kannel W. B., Ho K. K. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–1562, OS
  • Criqui M. H., Langer R. D., Fronek A., Feigelson H. S., Klauber M. R., McCann T. J., Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381–386, OS
  • Klag M. J., Whelton P. K., Randall B. L., Neaton J. D., Brancati F. L., Ford C. E., Shulman N. B., Stamler J. Blood pressure and end‐stage renal disease in men. N Engl J Med 1996; 334: 13–18, OS
  • Kearney P. M., Whelton M., Reynolds K., Muntner P., Whelton P. K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223, OS
  • Martiniuk A. L., Lee C. M., Lawes C. M., Ueshima H., Suh I., Lam T. H., Gu D., Feigin V., Jamrozik K., Ohkubo T., Woodward M., for the Asia‐Pacific Cohort Studies Collaboration. Hypertension: its prevalence and population‐attributable fraction for mortality from cardiovascular disease in the Asia‐Pacific region. J Hypertens 2007; 25: 73–79, OS
  • Wolf‐Maier K., Cooper R. S., Banegas J. R., Giampaoli S., Hense H. W., Joffres M., Kastarinen M., Poulter N., Primatesta P., Rodriguez‐Artalejo F., Stegmayr B., Thamm M., Tuomilehto J., Vanuzzo D., Vescio F. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–2369, OS
  • Ezzati M., Lopez A. D., Rodgers A., Vander Hoorn S., Murray C. J., Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360: 1347–1360, RV
  • Franklin S. S. Ageing and hypertension: the assessment of blood pressure indices in predicting coronary heart disease. J Hypertens 1999; 17((Suppl 5))S29–S36, RV
  • Benetos A., Zureik M., Morcet J., Thomas F., Bean K., Safar M., Ducimetiere P., Guize L. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000; 35: 673–680, OS
  • Staessen J. A., Gasowski J., Wang J. G., Thijs L., Den Hond E., Boissel J. P., Coope J., Ekbom T., Gueyffier F., Liu L., Kerlikowske K., Pocock S., Fagard R. H. Risks of untreated and treated isolated systolic hypertension in the elderly: meta‐analysis of outcome trials. Lancet 2000; 355: 865–872, MA
  • Darne B., Girerd X., Safar M., Cambien F., Guize L. Pulsatile versus steady component of blood pressure: a cross‐sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension 1989; 13: 392–400, OS
  • Benetos A., Safar M., Rudnichi A., Smulyan H., Richard J. L., Ducimetieere P., Guize L. Pulse pressure: a predictor of long‐term cardiovascular mortality in a French male population. Hypertension 1997; 30: 1410–1415, OS
  • Gasowski J., Fagard R. H., Staessen J. A., Grodzicki T., Pocock S., Boutitie F., Gueyffier F., Boissel J. P., INDANA Project Collaborators. Pulsatile blood pressure component as predictor of mortality in hypertension: a meta‐analysis of clinical trial control groups. J Hypertens 2002; 20: 145–151, MA
  • Blacher J., Staessen J. A., Girerd X., Gasowski J., Thijs L., Liu L., Wang J. G., Fagard R. H., Safar M. E. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085–1089, MA
  • Laurent S., Cockcroft J., Van Bortel L., Boutouyrie P., Giannattasio C., Hayoz D., Pannier B., Vlachopoulos C., Wilkinson I., Struijker‐Boudier H., on behalf of the European Network for non invasive investigation of large arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588–2605, GL
  • Pickering G. The nature of essential hypertension. J & A. Churchill Ltd, London 1961; 1–151, RV
  • Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo L., Jr., Jones D. W., Materson B. J., Oparil S., Wright J. T., Jr., Roccella E. J., National Heart, Lung, Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–1252, GL
  • Vasan R. S., Beiser A., Seshadri S., Larson M. G., Kannel W. B., D'Agostino R. B., Levy D. Residual lifetime risk for developing hypertension in middle‐aged women and men: The Framingham Heart Study. JAMA 2002; 287: 1003–1010, OS
  • Vasan R. S., Larson M. G., Leip E. P., Kannel W. B., Levy D. Assessment of frequency of progression to hypertension in non‐hypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682–1686, OS
  • Vasan R. S., Larson M. G., Leip E. P., Evans J. C., O'Donnell C. J., Kannel W. B., Levy D. Impact of high‐normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345: 1291–1297, OS
  • Mancia G., Grassi G. European, American and British Guidelines: similarities and differences. Hypertension. A companion to Braunwald's Heart diseases, H. R Black, W. J Elliott. Saunders‐Elsevier, Amsterdam 2007; 571–575
  • Kannel W. B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13((Suppl 1))S3–S10, OS
  • Thomas F., Rudnichi A., Bacri A. M., Bean K., Guize L., Benetos A. Cardiovascular mortality in hypertensive men according to presence of associated risk factors. Hypertension 2001; 37: 1256–1261, OS
  • Wei M., Mitchell B. D., Haffner S. M., Stern M. P. Effects of cigarette smoking, diabetes, high cholesterol, and hypertension on all‐cause mortality and cardiovascular disease mortality in Mexican Americans. The San Antonio Heart Study. Am J Epidemiol 1996; 144: 1058–1065, OS
  • Assmann G., Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116: 1713–1724, OS
  • Mancia G., Parati G., Borghi C., Ghironzi G., Andriani E., Marinelli L., Valentini M., Tessari F., Ambrosioni E. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens 2006; 24: 837–843, OS
  • Mancia G., Facchetti R., Bombelli M., Friz H. P., Grassi G., Giannattasio C., Sega R. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45: 1072–1077, OS
  • Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005; 112: 3384–3390, OS
  • Multiple Risk Factor Intervention Trial Research Group Relationship between baseline risk factors coronary heart disease total mortality in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Prev Med 1986; 15: 254–273, OS
  • Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. J Hypertens 1998; 16: 1407–1414, GL
  • De Backer G., Ambrosioni E., Borch‐Johnsen K., Brotons C., Cifkova R., Dallongeville J., Ebrahim S., Faergeman O., Graham I., Mancia G., Manger Cats V., Orth‐Gomer K., Perk J., Pyorala K., Rodicio J. L., Sans S., Sansoy V., Sechtem U., Silber S., Thomsen T., Wood D. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–1610, GL
  • D'Agostino R. B. S., Grundy S., Sullivan L. M., Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180–187, OS
  • Conroy R. M., Pyorala K., Fitzgerald A. P., Sans S., Menotti A., De Backer G., De Bacquer D., Ducimetiere P., Jousilahti P., Keil U., Njolstad I., Oganov R. G., Thomsen T., Tunstall‐Pedoe H., Tverdal A., Wedel H., Whincup P., Wilhelmsen L., Graham I. M. Estimation of ten‐year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987–1003, OS
  • World Health Organization/International Society of Hypertension. 2003. World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992, GL
  • Evans J. G., Rose G. Hypertension. Br Med Bull 1971; 27: 37–42, RV
  • Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation. Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Expert Panel on Detection Evaluation Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486–2497, GL
  • Dzau V. J., Antman E. M., Black H. R., Hayes D. L., Manson J. E., Plutzky J., Popma J. J., Stevenson W. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation 2006; 114: 2850–2870, RV
  • Cockroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41
  • Hallan S., Asberg A., Lindberg M., Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44: 84–93
  • Olsen M. H., Wachtell K., Bella J. N., Palmieri V., Gerdts E., Smith G., Nieminen M. S., Dahlof B., Ibsen H., Devereux R. B. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens 2004; 18: 453–459, OS
  • Willum‐Hansen T., Staessen J. A., Torp‐Pedersen C., Rasmussen S., Thijs L., Ibsen H., Jeppesen J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664–670, OS
  • Laurent S., Boutouyrie P., Asmar R., Gautier I., Laloux B., Guize L., Ducimetiere P., Benetos A. Aortic stiffness is an independent predictor of all‐cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236–1241, OS
  • Feringa H. H., Bax J. J., van Waning V. H., Boersma E., Elhendy A., Schouten O., Tangelder M. J., van Sambeek M. H., van den Meiracker A. H., Poldermans D. The long‐term prognostic value of the resting and postexercise ankle‐brachial index. Arch Intern Med 2006; 166: 529–535, OS
  • Devereux R. B., Wachtell K., Gerdts E., Boman K., Nieminen M. S., Papademetriou V., Rokkedal J., Harris K., Aurup P., Dahlof B. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350–2356, OS
  • Ibsen H., Olsen M. H., Wachtell K., Borch‐Johnsen K., Lindholm L. H., Mogensen C. E., Dahlof B., Devereux R. B., de Faire U., Fyhrquist F., Julius S., Kjeldsen S. E., Lederballe‐Pedersen O., Nieminen M. S., Omvik P., Oparil S., Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005; 45: 198–202, OS
  • de Zeeuw D., Remuzzi G., Parving H. H., Keane W. F., Zhang Z., Shahinfar S., Snapinn S., Cooper M. E., Mitch W. E., Brenner B. M. Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy. Circulation 2004; 110: 921–927, OS
  • Olsen M. H., Wachtell K., Ibsen H., Lindholm L. H., Dahlof B., Devereux R. B., Kjeldsen S. E., Oikarinen L., Okin P. M. LIFE Study Investigators. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24: 775–781, OS
  • Verdecchia P., Angeli F., Borgioni C., Gattobigio R., de Simone G., Devereux R. B., Porcellati C. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta‐analysis. Am J Hypertens 2003; 16: 895–899, MA
  • Benetos A., Rudnichi A., Thomas F., Safar M., Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 1999; 33: 44–52, OS
  • Palatini P., Thijs L., Staessen J. A., Fagard R. H., Bulpitt C. J., Clement D. L., de Leeuw P. W., Jaaskivi M., Leonetti G., Nachev C., O'Brien E. T., Parati G., Rodicio J. L., Roman E., Sarti C., Tuomilehto J., Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Predictive value of clinic, ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162: 2313–2321, OS
  • Kannel W. B., Kannel C., Paffenbarger R. S., Jr., Cupples L. A. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 1987; 113: 1489–1494, OS
  • Palatini P., Benetos A., Grassi G., Julius S., Kjeldsen S. E., Mancia G., Narkiewicz K., Parati G., Pessina A. C., Ruilope L. M., Zanchetti A. European Society of Hypertension Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24: 603–610, GL
  • Levy R. L., White P. D., Stroud W. D., Hillman C. C. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945; 129: 585–588, OS
  • King D. E., Everett C. J., Mainous A. G., 3rd., Liszka H. A. Long‐term prognostic value of resting heart rate in subjects with prehypertension. Am J Hypertens 2006; 19: 796–800, OS
  • Palatini P., Casiglia E., Pauletto P., Staessen J., Kaciroti N., Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension 1997; 30: 1267–1273, OS
  • Mancia G., Bombelli M., Corrao G., Facchetti R., Madotto F., Giannattasio C., Trevano F. Q., Grassi G., Zanchetti A., Sega R. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49: 40–47, OS
  • Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEARTstudy): case‐control study. Lancet 2004; 364: 937–952, OS
  • Fourth Joint Task Force of European other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2007, in preparation. GL
  • Mancia G., Ferrari A., Gregorini L., Parati G., Pomidossi G., Bertinieri G., Grassi G., di Rienzo M., Pedotti A., Zanchetti A. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 1983; 53: 96–104. OS
  • Sega R., Cesana G., Bombelli M., Grassi G., Stella M. L., Zanchetti A., Mancia G. Seasonal variations in home and ambulatory blood pressure in the PAMELA population. Pressione Arteriose Monitorate E Loro Associazioni. J Hypertens 1998; 16: 1585–1592. OS
  • Modesti P. A., Morabito M., Bertolozzi I., Massetti L., Panci G., Lumachi C., Giglio A., Bilo G., Caldara G., Lonati L., Orlandini S., Maracchi G., Mancia G., Gensini G. F., Parati G. Weather‐related changes in 24‐hour blood pressure profile: effects of age and implications for hypertension management. Hypertension 2006; 47: 155–161. OS
  • O'Brien E., Asmar R., Beilin L., Imai Y., Mallion J. M., Mancia G., Mengden T., Myers M., Padfield P., Palatini P., Parati G., Pickering T., Redon J., Staessen J., Stergiou G., Verdecchia P. European Society of Hypertension Recommendations for Conventional, Ambulatory and Home Blood Pressure Measurement. J Hypertens 2003; 21: 821–848. GL
  • O'Brien E., Waeber B., Parati G., Staessen J., Myers M. G. Blood pressure measuring devices: recommendations of the European Society of Hypertension. Br Med J 2001; 322: 531–536. GL
  • Mancia G., Omboni S., Parati G., Clement D. L., Haley W. E., Rahman S. N., Hoogma R. P. Twenty‐four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. J Hypertens 2001; 19: 1755–1763. OS
  • Mancia G., Omboni S., Ravogli A., Parati G., Zanchetti A. Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment: additional information from a large data base. Blood Press 1995; 4: 148–156. OS
  • Mancia G., Parati G., Bilo G., Maronati A., Omboni S., Hennig M., Zanchetti A. Assessment of long‐term antihypertensive treatment by clinic an ambulatory blood pressure. Data from the ELSA Study. J Hypertens 2007; 25: 1087–1094. OS
  • Fagard R. H., Staessen J. A., Thijs L. Relationships between changes in left ventricular mass and in clinic and ambulatory blood pressure in response to antihypertensive therapy. J Hypertens 1997; 15: 1493–1502. OS
  • Mancia G., Zanchetti A., Agabiti‐Rosei E., Benemio G., De Cesaris R., Fogari R., Pessina A., Porcellati C., Rappelli A., Salvetti A., Trimarco B. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment induced regression of left ventricular hypertrophy. Circulation 1997; 95: 1464–1470. OS
  • Fagard R. H., Staessen J. A., Thijs L. Prediction of cardiac structure and function by repeated clinic and ambulatory blood pressure. Hypertension 1997; 29: 22–29. OS
  • Verdecchia P., Schillaci G., Guerrieri M., Gatteschi C., Benemio G., Boldrini F., Porcellati C. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81: 528–536. OS
  • Mancia G., Parati G., Hennig M., Flatau B., Omboni S., Glavina F., Costa B., Scherz R., Bond G., Zanchetti A. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2001; 19: 1981–1989. OS
  • Redon J., Baldo E., Lurbe E., Bertolin V., Lozano J. V., Miralles A., Pascual J. M. Microalbuminuria, left ventricular mass and ambulatory blood pressure in essential hypertension. Kidney Int Suppl 1996; 55: S81–S84. OS
  • Imai Y., Ohkubo T., Sakuma M., Tsuji I. I., Satoh H., Nagai K., Hisamichi S., Abe K. Predictive power of screening blood pressure, ambulatory blood pressure and blood pressure measured at home for overall and cardiovascular mortality: a prospective observation in a cohort from Ohasama, Northern Japan. Blood Press Monit 1996; 1: 251–254. OS
  • Staessen J. A., Thijs L., Fagard R., O'Brien E. T., Clement D., de Leeuw P. W., Mancia G., Nachev C., Palatini P., Parati G., Tuomilehto J., Webster J. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999; 282: 539–546. OS
  • Clement D. L., De Buyzere M. L., De Bacquer D. A., de Leeuw P. W., Duprez D. A., Fagard R. H., Gheeraert P. J., Missault L. H., Braun J. J., Six R. O., Van Der Niepen P., O'Brien E. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. New Engl J Med 2003; 348: 2407–2415. OS
  • Sega R., Facchetti R., Bombelli M., Cesana G., Corrao G., Grassi G., Mancia G. Prognostic value of ambulatory and home blood pressure compared with office blood pressure in the general population: follow‐up results from the PAMELA study. Circulation 2005; 111: 1777–1783. OS
  • Fagard R. H., Celis H. Prognostic significance of various characteristics of out‐of‐the‐office blood pressure. J Hypertens 2004; 22: 1663–1666. OS
  • Dolan E., Stanton A., Thijs L., Hinedi K., Atkins N., McClory S., Den Hond E., McCormack P., Staessen J. A., O'Brien E. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality. Hypertension 2005; 46: 156–161. OS
  • Fagard R. H., Van Den Broeke C., De Cort P. Prognostic significance of blood pressure measured in the office, at home and during ambulatory monitoring in older patients in general practice. J Hum Hypertens 2005; 19: 801–807. OS
  • Hansen T. W., Jeppesen J., Rasmussen S., Ibsen H., Torp‐Pedersen C. Ambulatory blood pressure and mortality. A population‐based study. Hypertension 2005; 45: 499–504. OS
  • Kikuya M., Ohkubo T., Asayama K., Metoki H., Obara T., Saito S., Hashimoto J., Totsune K., Hoshi H., Satoh H., Imai Y. Ambulatory blood pressure and 10‐year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 2005; 45: 240–245. OS
  • Pickering T. G., Shimbo D., Haas D. Ambulatory blood pressure monitoring. New Engl J Med 2006; 354: 2368–2374. RV
  • Redon J., Campos C., Narciso M. L., Rodicio J. L., Pascual J. M., Ruilope L. M. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31: 712–718. OS
  • Coats A. J. S., Radaelli A., Clark S. J., Conway J., Sleight P. The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension. J Hypertension 1992; 10: 385–391. OS
  • Mancia G., Ulian L., Parati G., Trazzi S. Increase in blood pressure reproducibility by repeated semi‐automatic blood pressure measurements in the clinic environment. J Hypertens 1994; 12: 469–473. OS
  • Parati G., Pomidossi G., Casadei V., Mancia G. Lack of alerting reactions and pressor responses to intermittent cuff inflations during non‐invasive blood pressure monitoring. Hypertension 1985; 7: 597–601. OS
  • Mancia G., Omboni S., Parati G., Ravogli A., Villani A., Zanchetti A. Lack of placebo effect on ambulatory blood pressure. Am J Hypertens 1995; 8: 311–315. OS
  • Staessen J. A., Thijs L., Clement D., Davidson C., Fagard R., Lehtonen A., Mancia G., Palatini P., O'Brien E. T., Parati G., Webster J., Amery A. Ambulatory blood pressure decreases on long‐term placebo treatment in older patients with isolated systolic hypertension. J Hypertens 1994; 12: 1035–1039. OS
  • O'Brien E., Sheridan J., O'Malley K. Dippers and non‐dippers. Lancet 1988; 2: 397. RV
  • Ohkubo T., Hozawa A., Yamaguchi J., Kikuya M., Ohmori K., Michimata M., Matsubara M., Hashimoto J., Hoshi H., Araki T., Tsuji I., Satoh H., Hisamichi S., Imai Y. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24‐h blood pressure: the Ohasama study. J Hypertens 2002; 20: 2183–2189. OS
  • Verdecchia P., Porcellati C., Schillaci G., Borgioni C., Ciucci A., Battistelli M., Guerrieri M., Gatteschi C., Zampi I., Santucci A. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793–801. OS
  • Metoki H., Ohkubo T., Kikuya M., Asayama K., Obara T., Hashimoto J., Totsune K., Hoshi H., Satoh H., Imai Y. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline, The Ohasama Study. Hypertension 2006; 47: 149–154. OS
  • Hansen T. W., Jeppesen J., Rasmussen S., Ibsen H., Torp‐Pedersen C. Ambulatory blood pressure monitoring and risk of cardiovascular disease: a population based study. Am J Hypertens 2006; 19: 243–250. OS
  • Willich S. N., Goldberg R. J., Maclure M., Perriello L., Muller J. E. Increased onset of sudden cardiac death in the first three hours after awakening. Am J Cardiol 1992; 70: 65–68. OS
  • Rocco M. B., Barry J., Campbell S., Nabel E., Cook E. F., Goldman L., Selwyn A. P. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation 1987; 75: 395–400. OS
  • Muller J. E., Stone P. H., Turi Z. G., Rutherford J. D., Czeisler C. A., Parker C., Poole W. K., Passamani E., Roberts R., Robertson T. Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 1985; 313: 1315–1322. OS
  • Elliott W. J. Circadian variation in the timing of stroke onset: a meta‐analysis. Stroke 1998; 29: 992–996. MA
  • Millar‐Craig M. W., Bishop C. N., Raftery E. B. Circadian variation of blood‐pressure. Lancet 1978; 1: 795–797. OS
  • Kario K., Pickering T. G., Umeda Y., Hoshide S., Hoshide Y., Morinari M., Murata M., Kuroda T., Schwartz J. E., Shimada K. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–1406. OS
  • Mancia G., Zanchetti A. Cardiovascular regulation during sleep. Handbook of Physiology during Sleep, J Orem. Academic Press, New York 1980; 1–55. RV
  • El‐Tamimi H., Mansour M., Pepine C. J., Wargovich T. J., Chen H. Circadian variation in coronary tone in patients with stable angina. Protective role of the endothelium. Circulation 1995; 92: 3201–3205. OS
  • Otto M. E., Svatikova A., Barretto R. B., Santos S., Hoffmann M., Khandheria B., Somers V. Early morning attenuation of endothelial function in healthy humans. Circulation 2004; 109: 2507–2510. OS
  • Brown N. J., Agirbasli M. A., Williams G. H., Litchfield W. R., Vaughan D. E. Effect of activation and inhibition of the renin‐angiotensin system on plasma PAI‐1. Hypertension 1998; 32: 965–971. OS
  • Weber M. A. The 24‐hour blood pressure pattern: does it have implications for morbidity and mortality?. Am J Cardiol 2002; 89: 27A–33A. RV
  • Undar L., Turkay C., Korkmaz L. Circadian variation in circulating platelet aggregates. Ann Med 1989; 21: 429–433. OS
  • Frattola A., Parati G., Cuspidi C., Albini F., Mancia G. Prognostic value of 24‐hour blood pressure variability. J Hypertens 1993; 11: 1133–1137. OS
  • Sander D., Kukla C., Klingelhofer J., Winbeck K., Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3‐year follow‐up study. Circulation 2000; 102: 1536–1541. OS
  • Verdecchia P., Borgioni C., Ciucci A., Gattobigio R., Schillaci G., Sacchi N., Santucci A., Santucci C., Reboldi G., Porcellati C. Prognostic significance of blood pressure variability in essential hypertension. Blood Press Monit 1996; 1: 3–11. OS
  • Mancia G., Bombelli M., Facchetti R., Madotto F., Corrao G., Quarti‐Trevano F., Grassi G., Sega R. Long term prognostic value of blood pressure variability in the general population: result of the PAMELA study. Hypertension 2007, in press. OS
  • Staessen J., Fagard R. H., Lijnen P. J., Van Hoof R., Amery A. K. Mean and range of the ambulatory pressure in normotensive subjects from a meta‐analysis of 23 studies. Am J Cardiol 1991; 67: 723–727. MA
  • Mancia G., Sega R., Bravi C., De Vito G., Valagussa F., Cesana G., Zanchetti A. Ambulatory blood pressure normality: results from the PAMELA Study. J Hypertens 1995; 13: 1377–1390. OS
  • Ohkubo T., Imai Y., Tsuji I., Nagai K., Ito S., Satoh H., Hisamichi S. Reference values for 24‐hour ambulatory blood pressure monitoring based on a prognostic criterion: the Ohasama Study. Hypertension 1998; 32: 255–259. OS
  • Sakuma M., Imai Y., Nagai K., Watanabe N., Sakuma H., Minami N., Satoh H., Abe K. Reproducibility of home blood pressure measurements over a 1‐year period. Am J Hypertens 1997; 10: 798–803. OS
  • Ohkubo T., Imai Y., Tsuji I., Nagai K., Kato J., Kikuchi N., Nishiyama A., Aihara A., Sekino M., Kikuya M., Ito S., Satoh H., Hisamichi S. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure measurement: a population‐based observation in Ohasama, Japan. J Hypertens 1998; 16: 971–975. OS
  • Zarnke K. B., Feagan B. G., Mahon J. L., Feldman R. D. A randomized study comparing a patient‐directed hypertension management strategy with usual office‐based care. Am J Hypertens 1997; 10: 58–67. OS
  • Pickering T., James G. D., Boddie C., Hrashfield G. A., Blank S., Laragh J. H. How common is white coat hypertension?. JAMA 1988; 259: 225–228. OS
  • Parati G., Ulian L., Santucci C., Omboni S., Mancia G. Difference between clinic and daytime blood pressure is not a measure of the white coat effect. Hypertension 1998; 31: 1185–1189. OS
  • Mancia G., Bertinieri G., Grassi G., Parati G., Pomidossi G., Ferrari A., Gregorini L., Zanchetti A. Effects of blood‐pressure measurement by the doctor on patient's blood pressure and heart rate. Lancet 1983; 2: 695–698. OS
  • Mancia G., Parati G., Pomidossi G., Grassi G., Casadei R., Zanchetti A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9: 209–215. OS
  • Mancia G., Facchetti R., Bombelli M., Grassi G., Sega R. Long‐term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006; 47: 846–853. OS
  • Ohkubo T., Kikuya M., Metoki H., Asayama K., Obara T., Hashimoto J., Totsune K., Hoshi H., Satoh H., Imai Y. Prognosis of masked hypertension and white‐coat hypertension detected by 24‐h ambulatory blood pressure monitoring. J Am Coll Cardiol 2005; 46: 508–515. OS
  • Khattar R. S., Senior R., Lahiri A. Cardiovascular outcome in white‐coat versus sustained mild hypertension. A 10‐year follow‐up study. Circulation 1998; 98: 1892–1897. OS
  • Fagard R. H., Staessen J. A., Thijs L., Gasowski J., Bulpitt C. J., Clement D., de Leeuw P. W., Dobovisek J., Jaaskivi M., Leonetti G., O'Brien E., Palatini P., Parati G., Rodicio J. L., Vanhanen H., Webster J. Response to antihypertensive treatment in older patients with sustained or nonsustained systolic hypertension. Circulation 2000; 102: 1139–1144. OS
  • Bobrie G., Chatellier G., Genes N., Clerson P., Vaur L., Vaisse B., Menard J., Mallion J. M. Cardiovascular prognosis of ‘masked hypertension’ detected by blood pressure self‐measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342–1349. OS
  • Verdecchia P., Reboldi G. P., Angeli F., Schillaci G., Schwartz J. E., Pickering T. G., Imai Y., Ohkubo T., Kario K. Short‐ and long‐term incidence of stroke in white‐coat hypertension. Hypertension 2005; 45: 203–208. OS
  • Sega R., Trocino G., Lanzarotti A., Carugo S., Cesana G., Schiavina R., Valagussa F., Bombelli M., Giannattasio C., Zanchetti A., Mancia G. Alterations of cardiac structure in patients with isolated office, ambulatory or home hypertension. Data from the general PAMELA population. Circulation 2001; 104: 1385–1392. OS
  • Wing L. M. H., Brown M. A., Beilin L. J., Ryan P., Reid C. Reverse white‐coat hypertension in older hypertensives. J Hypertens 2002; 20: 639–644. OS
  • Bjorklund K., Lind L., Zethelius B., Andren B., Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation 2003; 107: 1297–1302. OS
  • Lurbe E., Torro I., Alvarez V., Nawrot T., Paya R., Redon J., Staessen J. A. Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension 2005; 45: 493–498. OS
  • Mancia G., Parati G. Reactivity to physical and behavioral stress and blood pressure variability in hypertension. Handbook of Hypertension. Vol 9. Behavioral Factors in Hypertension, S Julius, D. R Bassett, 1987; 104–122. RV
  • Pescatello L. S., Franklin B. A., Fagard R., Farquhar W. B., Kelley G. A., Ray C. A. American College of Sports Medicine Position Stand: Exercise and Hypertension. Med Sci Sports Exerc 2004; 36: 533–553. GL
  • Singh J. P., Larson M. G., Manolio T. A., O'Donnell C. J., Lauer M., Evans J. C., Levy D. Blood pressure response during treadmill testing as a risk factor for new‐onset hypertension: the Framingham Heart Study. Circulation 1999; 99: 1831–1836. OS
  • Carroll D., Smith G. D., Shipley M. J., Steptoe A., Brunner E. J., Marmot M. G. Blood pressure reactions to acute psychological stress and future blood pressure status: a 10‐year follow‐up of men in the Whitehall II study. Psychosom Med 2001; 63: 737–743. OS
  • Manolio T. A., Burke G. L., Savage P. J., Sidney S., Gardin J. M., Oberman A. Exercise blood pressure response and 5‐year risk of elevated blood pressure in a cohort of young adults: the CARDIA study. Am J Hypertens 1994; 7: 234–241. CT
  • Fagard R., Staessen J., Amery A. Exercise blood pressure and target organ damage in essential hypertension. J Hum Hypertension 1991; 5: 69–75. OS
  • Filipovsky J., Ducimetiere P., Safar M. Prognostic significance of exercise blood pressure and heart rate in middle‐aged men. Hypertension 1992; 20: 337–339. OS
  • Lauer M. S., Levy D., Anderson K. M., Plehn J. F. Is there a relationship between exercise systolic blood pressure response and left ventricular mass?. Ann Intern Med 1992; 116: 203–210. OS
  • Smith D. H. G., Neutel J. M., Graettinger W. F., Myers J., Froelicher V. F., Weber M. A. Impact of left ventricular hypertrophy on blood pressure responses to exercise. Am J Cardiol 1992; 69: 225–228. OS
  • Fagard R., Staessen J., Thijs L., Amery A. Relation of left ventricular mass and filling to exercise blood pressure and rest blood pressure. Am J Cardiol 1995; 75: 53–57. OS
  • Markovitz J. H., Raczynski J. M., Lewis C. E., Flack J., Chesney M., Chettur V., Hardin J. M., Johnson E. Lack of independent relationships between left ventricular mass and cardiovascular reactivity to physical and psychological stress in the CARDIA study. Am J Hypertens 1996; 9: 915–923. OS
  • Fagard R. H., Pardaens K., Staessen J. A., Thijs L. Should exercise blood pressure be measured in clinical practice?. J Hypertens 1998; 16: 1215–1217. RV
  • Kokkinos P., Pittaras A., Narayan P., Faselis C., Singh S., Manolis A. Exercise capacity and blood pressure associations with left ventricular mass in prehypertensive individuals. Hypertension 2007; 49: 55–61. OS
  • Al'Absi M., Devereux R. B., Lewis C. E., Kitzman D. W., Rao D. C., Hopkins P., Markovitz J., Arnett D. K. Blood pressure responses to acute stress and left ventricular mass. Am J Cardiol 2002; 89: 536–540. OS
  • Rostrup M., Smith G., Bjornstad H., Westheim A., Stokland O., Eide I. Left ventricular mass and cardiovascular reactivity in young men. Hypertension 1994; 23((Suppl I))I168–I171. OS
  • Al'Absi M., Devereux R. B., Rao D. C., Kitzman D., Oberman A., Hopkins P., Arnett D. K. Blood pressure stress reactivity and left ventricular mass in a random community sample of African‐American and Caucasian men and women. Am J Cardiol 2006; 97: 240–244. OS
  • Fagard R. H., Pardaens K., Staessen J. A., Thijs L. Prognostic value of invasive hemodynamic measurements at rest and during exercise in hypertensive men. Hypertension 1996; 28: 31–36. OS
  • Kjeldsen S. E., Mundal R., Sandvik L., Erikssen G., Thaulow E., Erikssen J. Supine and exercise systolic blood pressure predict cardiovascular death in middle‐aged men. J Hypertens 2001; 19: 1343–1348. OS
  • Palatini P. Exaggerated blood pressure response to exercise: pathophysiologic mechanisms and clinical relevance. J Sports Med Phys Fitness 1998; 38: 1–9. OS
  • O' Rourke M. F. Principles and definitions of arterial stiffness, wave reflections and pulse pressure amplification. Arterial stiffness in hypertension. Handbook of Hypertension, M. E Safar, M. F O'Rourke, 2006; Vol 23: 3–19, Elsevier
  • Morgan T., Lauri J., Bertram D., Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004; 17: 118–123
  • Chen C. H., Nevo E., Fetics B., Pak P. H., Yin F. C., Maughan W. L., Kass D. A. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation 1997; 95: 1827–1836
  • Hope S. A., Tay D. B., Meredith I. T., Cameron J. D. Use of arterial transfer functions for the derivation of aortic waveform characteristics. J Hypertens 2003; 21: 1299–1305
  • Williams B., Lacy P. S., Thom S. M., Cruickshank K., Stanton A., Collier D., Hughes A. D., Thurston H., O'Rourke M., CAFE Investigators Anglo‐Scandinavian Cardiac Outcomes Trial Investigators CAFE Steering Committee, Writing Committee. Differential impact of blood pressure‐lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213–1225. RT
  • Dhakam Z., McEniery C. M., Yasmin, Cockcroft J. R., Brown M. J., Wilkinson I. B. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006; 19: 214–219. RT
  • Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M. J., Cosentino F., Jonsson B., Laakso M., Malmberg K., Priori S., Ostergren J., Tuomilehto J., Thrainsdottir I., Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre‐diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136. GL
  • Ridker P. M. High‐sensitivity C‐reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813–1818. OS
  • Wang T. J., Gona P., Larson M. G., Tofler G. H., Levy D., Newton‐Cheh C., Jacques P. F., Rifai N., Selhub J., Robins S. J., Benjamin E. J., D'Agostino R. B., Vasan R. S. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631–2639. OS
  • Ridker P. M., Buring J. E., Cook N. R., Rifai N. C‐reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8‐year follow‐up of 14719 initially healthy American women. Circulation 2003; 107: 391–397. OS
  • Sattar N., Gaw A., Scherbakova O., Ford I., O'Reilly D. S., Haffner S. M., Isles C., Macfarlane P. W., Packard C. J., Cobbe S. M., Shepherd J. Metabolic syndrome with and without C‐reactive protein as a predictor of coronary heart disease and diabetes in the West Of Scotland Coronary Prevention Study. Circulation 2003; 108: 414–419. OS
  • Olsen M. H., Wachtell K., Tuxen C., Fossum E., Bang L. E., Hall C., Ibsen H., Rokkedal J., Devereux R. B., Hildebrandt P. N‐terminal pro‐brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004; 22: 1597–1604. OS
  • Luft F. C. Molecular genetics of human hypertension. J Hypertens 1998; 16: 1871–1878. RV
  • Melander O. Genetic factors in hypertension‐what is known and what does it mean?. Blood Press 2001; 10: 254–270. RV
  • Cadman P. E., O'Connor D. T. Pharmacogenomics of hypertension. Curr Opin Nephrol Hypertens 2003; 12: 61–70. RV
  • Lifton R. P., Gharavi A. G., Geller D. S. Molecular mechanisms of human hypertension. Cell 2001; 104: 545–556. RV
  • Jensen J. S., Feldt‐Rasmussen B., Strandgaard S., Schroll M., Borch‐Johnsen K. Arterial hypertension microalbuminuria risk of ischemic heart disease. Hypertension 2000; 35: 898–903. OS
  • De Leeuw P. W., Ruilope L. M., Palmer C. R., Brown M. J., Castaigne A., Mancia G., Rosenthal T., Wagener G. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459–2464. RT
  • Sarnak M. J., Levey A. S., Schoolwerth A. C., Coresh J., Culleton B., Hamm L. L., McCullough P. A., Kasiske B. L., Kelepouris E., Klag M. J., Parfrey P., Pfeffer M., Raij L., Spinosa D. J., Wilson P. W., American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154–2169. GL
  • Gerstein H. C., Mann J. F., Yi Q., Zinman B., Dinneen S. F., Hoogwerf B., Halle J. P., Young J., Rashkow A., Joyce C., Nawaz S., Yusuf S., HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421–426. OS
  • Wachtell K., Ibsen H., Olsen M. H., Borch‐Johnsen K., Lindholm L. H., Mogensen C. E., Dahlof B., Devereux R. B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S. E., Kristianson K., Lederballe‐Pedersen O., Nieminen M. S., Okin P. M., Omvik P., Oparil S., Wedel H., Snapinn S. M., Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901–906. OS
  • Jager A., Kostense P. J., Ruhe H. G., Heine R. J., Nijpels G., Dekker J. M., Bouter L. M., Stehouwer C. D. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all‐cause mortality, especially among hypertensive subjects: five‐year follow‐up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19: 617–624. OS
  • Bigazzi R., Bianchi S., Baldari D., Campese V. M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325–1333. OS
  • Hillege H. L., Fidler V., Diercks G. F., van Gilst W. H., de Zeeuw D., van Veldhuisen D. J., Gans R. O., Janssen W. M., Grobbee D. E., de Jong P. E., Prevention of Renal, Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–1782. OS
  • National Kidney Foundation. Executive summary. Am J Kid Dis 2004; 43((Suppl. 1))S16–S33. RV
  • Levy D., Salomon M., D'Agostino R. B., Belanger A. J., Kannel W. B. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786–1793. OS
  • Levy D., Garrison R. J., Savage D. D., Kannel W. B., Castelli W. P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561–1566. OS
  • Koren M. J., Devereux R. B., Casale P. N., Savage D. D., Laragh J. H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345–352. OS
  • Salonen J. T., Salonen R. Ultrasound B‐mode imaging in observational studies of atherosclerotic progression. Circulation 1993; 87((Suppl II))II56–II65. OS
  • Bots M. L., Hoes A. W., Koudstaal P. J., Hofman A., Grobbee D. E. Common carotid intima‐media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation 1997; 96: 1432–1437. OS
  • Hodis H. N., Mack W. J., LaBree L., Selzer R. H., Liu C. R., Liu C. H., Azen S. P. The role of carotid arterial intima‐media thickness in predicting clinical coronary events. Ann Intern Med 1998; 128: 262–269. OS
  • O'Leary D. H., Polak J. F., Kronmal R. A., Manolio T. A., Burke G. L., Wolfson S. K., Jr. Carotid‐artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999; 340: 14–22. OS
  • Cuspidi C., Ambrosioni E., Mancia G., Pessina A. C., Trimarco B., Zanchetti A. Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension: the Assessment of Prognostic Risk Observational Survey. J Hypertens 2002; 20: 1307–1314. OS
  • Okin P. M., Devereux R. B., Jern S., Kjeldsen S. E., Julius S., Nieminen M. S., Snapinn S., Harris K. E., Aurup P., Edelman J. M., Wedel H., Lindholm L. H., Dahlof B., LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292: 2343–2349. OS
  • Fagard R. H., Staessen J. A., Thijs L., Celis H., Birkenhager W. H., Bulpitt C. J., de Leeuw P. W., Leonetti G., Sarti C., Tuomilehto J., Webster J., Yodfat Y., Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension. Hypertension 2004; 44: 459–464. OS
  • La Rovere M. T., Pinna G. D., Maestri R., Mortara A., Capomolla S., Febo O., Ferrari R., Franchini M., Gnemmi M., Opasich C., Riccardi P. G., Traversi E., Cobelli F. Short‐term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003; 107: 565–570. OS
  • Bigger J. T., Jr., Fleiss J. L., Steinman R. C., Rolnitzky L. M., Kleiger R. E., Rottman J. N. Frequency domain measures of heart period variability and mortality after myocardial infarction. Circulation 1992; 85: 164–171. OS
  • Kleiger R. E., Miller J. P., Bigger J. T., Jr., Moss A. J., for the Multicentre Post‐Infarction Research Group. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59: 256–262. OS
  • Reichek N., Devereux R. B. Left ventricular hypertrophy: relationship of anatomic, echocardiographic and electrocardiographic findings. Circulation 1981; 63: 1391–1398. OS
  • Devereux R. B., Alonso D. R., Lutas E. M., Gottlieb G. J., Campo E., Sachs I., Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450–458. OS
  • Lang R. M., Bierig M., Devereux R. B., Flachskampf F. A., Foster E., Pellikka P. A., Picard M. H., Roman M. J., Seward J., Shanewise J., Solomon S., Spencer K. T., St John Sutton M., Stewart W. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography. European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79–108. GL
  • Jennings G., Wong J. Reversibility of left ventricular hypertrophy and malfunction by antihypertensy treatment. Handbook of Hypertension, L Hansson, W. H Birkenhager. Elsevier Science, Amsterdam 1997; 184–223. RV, Vol 18
  • Muiesan M. L., Salvetti M., Monteduro C., Bonzi B., Paini A., Viola S., Poisa P., Rizzoni D., Castellano M., Agabiti‐Rosei E. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004; 43: 731–738. OS
  • De Simone G., Devereux R. B., Koren M. J., Mensah G. A., Casale P. N., Laragh J. H. Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 1996; 93: 259–265. OS
  • Aurigemma G. P., Gottdiener J. S., Shemanski L., Gardin J., Kitzman D. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: The Cardiovascular Health Study. J Am Coll Cardiol 2001; 37: 1042–1048. OS
  • Swedberg K., Cleland J., Dargie H., Drexler H., Follath F., Komajda M., Tavazzi L., Smiseth O. A., Gavazzi A., Haverich A., Hoes A., Jaarsma T., Korewicki J., Levy S., Linde C., Lopez‐Sendon J. L., Nieminen M. S., Pierard L., Remme W. J., Task Force for the Diagnosis, Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115–1140. GL
  • Ogunyankin K. O., Burggraf G. W., Abiose A. K., Malik P. G. Validity of revised Doppler echocardiographic algorithms and composite clinical and angiographic data in diagnosis of diastolic dysfunction. Echocardiography 2006; 23: 817–828. OS
  • Bursi F., Weston S. A., Redfield M. M., Jacobsen S. J., Pakhomov S., Nkomo V. T., Meverden R. A., Roger V. L. Systolic and diastolic heart failure in the community. JAMA 2006; 296: 2209–2216. OS
  • Zanchetti A., Agabiti‐Rosei E., Ambrosioni E., Chiariello N., Leonetti G., Mancia G., Pessina A. C., Rizzon P., Salvetti A., Trimarco B., Volpe M. Left ventricular diastolic dysfunction in a cohort of hypertensive patients attending hospital outpatient clinics in Italy, the APROS‐DIADYS project. J Hypertension 2006; 24((suppl 6))41. (abstract). OS
  • Tsang T. S., Barnes M. E., Gersh B. J., Bailey K. R., Seward J. B. Risks for atrial fibrillation and congestive heart failure in patients ⩾65 years of age with abnormal left ventricular diastolic relaxation. Am J Cardiol 2004; 93: 54–58. OS
  • Redfield M. M., Jacobsen S. J., Burnett J. C., Jr., Mahoney D. W., Bailey K. R., Rodeheffer R. J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194–202. OS
  • Bella J. N., Palmieri V., Roman M. J., Liu J. E., Welty T. K., Lee E. T., Fabsitz R. R., Howard B. V., Devereux R. B. Mitral ratio of peak early to late diastolic filling velocity as a predictor of mortality in middle‐aged and elderly adults. The Strong Heart Study. Circulation 2002; 105: 1928–1933. OS
  • Laukkanen J. A., Kurl S., Eranen J., Huttunen M., Salonen J. T. Left atrium size and the risk of cardiovascular death in middle‐aged men. Arch Intern Med 2005; 165: 1788–1793. OS
  • Verdecchia P., Reboldi G., Gattobigio R., Bentivoglio M., Borgioni C., Angeli F., Carluccio E., Sardone M. G., Porcellati C. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41: 218–223. OS
  • Kizer J. R., Bella J. N., Palmieri V., Liu J. E., Best L. G., Lee E. T., Roman M. J., Devereux R. B. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle‐aged and elderly adults: the Strong Heart Study (SHS). Am Heart J 2006; 151: 412–418. OS
  • Ciulla M., Paliotti R., Hess D. B., Tjahja E., Campbell S. E., Magrini F., Weber K. T. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. J Am Soc Echocardiogr 1997; 10: 657–664. OS
  • Hoyt R. M., Skorton D. J., Collins S. M., Melton H. E. Ultrasonic backscatter and collagen in normal ventricular myocardium. Circulation 1984; 69: 775–782. OS
  • Ciulla M. M., Paliotti R., Esposito A., Diez J., Lopez B., Dahlof B., Nicholls M. G., Smith R. D., Gilles L., Magrini F., Zanchetti A. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004; 110: 552–557. RT
  • Zanchetti A., Bond M. G., Hennig M., Neiss A., Mancia G., Dal Palu C., Hansson L., Magnani B., Rahn K. H., Reid J. L., Rodicio J., Safar M., Eckes L., Rizzini P., European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double‐blind, long‐term trial. Circulation 2002; 106: 2422–2427. RT
  • Zanchetti A., Bond M. G., Hennig M., Tang R., Hollweck R., Mancia G., Eckes L., Micheli D., ELSA Investigators. Absolute and relative changes in carotid intima‐media thickness and atherosclerotic plaques during long‐term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2004; 22: 1201–1212. RT
  • Zanchetti A., Agabiti Rosei E., Dal Palu C., Leonetti G., Magnani B., Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): results of long‐term randomized treatment with either verapamil or chlorthalidone on carotid intima‐media thickness. J Hypertens 1998; 16: 1667–1676. RT
  • Hiatt W. R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608–1621. RV
  • Vogt M. T., Cauley J. A., Newman A. B., Kuller L. H., Hulley S. B. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465–469. OS
  • McKenna M., Wolfson S., Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119–128. OS
  • Vogt M. T., McKenna M., Anderson S. J., Wolfson S. K., Kuller L. H. The relationship between ankle‐arm index and mortality in older men and women. J Am Geriatr Soc 1993; 41: 523–530. OS
  • Burek K. A., Sutton‐Tyrrell K., Brooks M. M., Naydeck B., Keller N., Sellers M. A., Roubin G., Jandova R., Rihal C. S. Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 1999; 34: 716–721. OS
  • Safar M. E., Levy B. I., Struijker‐Boudier H. Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 2003; 107: 2864–2869. RV
  • Laurent S., Katsahian S., Fassot C., Tropeano A. I., Laloux B., Boutouyrie P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34: 1203–1206. OS
  • Boutouyrie P., Tropeano A. I., Asmar R., Gautier I., Benetos A., Lacolley P., Laurent S. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39: 10–15. OS
  • Park J. B., Schiffrin E. L. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertension 2001; 19: 921–930. OS
  • Korsgaard N., Aalkjaer C., Heagerty A. M., Izzard A. S., Mulvany M. J. Histology of subcutaneous small arteries from patients with essential hypertension. Hypertension 1993; 22: 523–526
  • Rizzoni D., Porteri E., Guelfi D., Muiesan M. L., Valentini U., Cimino A., Girelli A., Rodella L., Bianchi R., Sleiman I., Agabiti‐Rosei E. Structural alterations in subcutaneous small arteries of normotensive and hypertensive patients with non‐insulin‐dependent diabetes mellitus. Circulation 2001; 103: 1238–1244
  • Schofield I., Malik R., Izzard A., Austin C., Heagerty A. Vascular structural and functional changes in type 2 diabetes mellitus: evidence for the roles of abnormal myogenic responsiveness and dyslipidemia. Circulation 2002; 106: 3037–3043. OS
  • Rizzoni D., Porteri E., Boari G. E., De Ciuceis C., Sleiman I., Muiesan M. L., Castellano M., Miclini M., Agabiti‐Rosei E. Prognostic significance of small‐artery structure in hypertension. Circulation 2003; 108: 2230–2235
  • Greenland P., Gaziano J. M. Clinical practice. Selecting asymptomatic patients for coronary computed tomography or electrocardiographic exercise testing. N Engl J Med 2003; 349: 465–473. RV
  • Heitzer T., Schlinzig T., Krohn K., Meinertz T., Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673–2678. OS
  • Halcox J. P., Schenke W. H., Zalos G., Mincemoyer R., Prasad A., Waclawiw M. A., Nour K. R., Quyyumi A. A. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653–665. OS
  • Taddei S., Salvetti A. Endothelial dysfunction in essential hypertension: clinical implications. J Hypertens 2002; 20: 1671–1674. RV
  • Werner N., Kosiol S., Schiegl T., Ahlers P., Walenta K., Link A., Bohm M., Nickenig G. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005; 353: 999–1007. OS
  • Stevens L. A., Coresh J., Greene T., Levey A. S. Assessing kidney function‐measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473–2483
  • Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., Ott S., Sprague S., Lameire N., Eknoyan G., Kidney Disease: Improving Global Outcomes (KDIGO). Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–2100. GL
  • Shlipak M. G., Katz R., Sarnak M. J., Fried L. F., Newman A. B., Stehman‐Breen C., Seliger S. L., Kestenbaum B., Psaty B., Tracy R. P., Siscovick D. S. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 2006; 145: 237–246. OS
  • Culleton B. F., Larson M. G., Wilson P. W., Evans J. C., Parfrey P. S., Levy D. Cardiovascular disease and mortality in a community‐based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214–2219. OS
  • Parving H. H. Initiation and progression of diabetic nephropathy. N Engl J Med 1996; 335: 1682–1683. RV
  • Ruilope L. M., Rodicio J. L. Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens 1993; 2: 962–967. RV
  • Redon J., Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20: 353–355. RV
  • Arnlov J., Evans J. C., Meigs J. B., Wang T. J., Fox C. S., Levy D., Benjamin E. J., D'Agostino R. B., Vasan R. S. Low‐grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969–975. OS
  • Zanchetti A., Hansson L., Dahlof B., Elmfeldt D., Kjeldsen S., Kolloch R., Larochelle P., McInnes G. T., Mallion J. M., Ruilope L., Wedel H. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001; 19: 1149–1159. OS
  • Ruilope L. M., Salvetti A., Jamerson K., Hansson L., Warnold I., Wedel H., Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218–225. RT
  • De Leeuw P. W., Thijs L., Birkenhager W. H., Voyaki S. M., Efstratopoulos A. D., Fagard R. H., Leonetti G., Nachev C., Petrie J. C., Rodicio J. L., Rosenfeld J. J., Sarti C., Staessen J. A., Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst‐Eur trial. J Am Soc Nephrol 2002; 13: 2213–2222. OS
  • Segura J., Ruilope L. M., Zanchetti A. On the importance of estimating renal function for cardiovascular risk assessment. J Hypertens 2004; 22: 1635–1639. RV
  • Rahman M., Pressel S., Davis B. R., Nwachuku C., Wright J. T., Jr., Whelton P. K., Barzilay J., Batuman V., Eckfeldt J. H., Farber M. A., Franklin S., Henriquez M., Kopyt N., Louis G. T., Saklayen M., Stanford C., Walworth C., Ward H., Wiegmann T., ALLHAT Collaborative Research Group. Cardiovascular outcomes in high‐risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144: 172–180. OS
  • Keith N. H., Wagener H. P., Barker M. W. Some different types of essential hypertension: their course and prognosis. Am J Med Sci 1939; 197: 332–343. OS
  • Cuspidi C., Macca G., Salerno M., Michev L., Fusi V., Severgnini B., Corti C., Meani S., Magrini F., Zanchetti A. Evaluation of target organ damage in arterial hypertension: which role for qualitative funduscopic examination?. Ital Heart J 2001; 2: 702–706. OS
  • Dimmitt S. B., West J. N., Eames S. M., Gibson J. M., Gosling P., Littler W. A. Usefulness of ophthalmoscopy in mild to moderate hypertension. Lancet 1989; 1: 1103–1106. OS
  • Fuchs F. D., Maestri M. K., Bredemeier M., Cardozo S. E., Moreira F. C., Wainstein M. V., Moreira W. D., Moreira L. B. Study of the usefulness of optic fundi examination of patients with hypertension in a clinical setting. J Hum Hypertens 1995; 9: 547–551. OS
  • Wong T. Y., Klein R., Sharrett A. R., Duncan B. B., Couper D. J., Tielsch J. M., Klein B. E., Hubbard L. D. Retinal arteriolar narrowing and risk of coronary heart disease in men and women. The Atherosclerosis Risk in Communities Study. JAMA 2002; 287: 1153–1159. OS
  • Wong T. Y., Klein R., Sharrett A. R., Couper D. J., Klein B. E., Liao D. P., Hubbard L. D., Mosley T. H., ARIC Investigators. Atheroslerosis Risk in Communities Study. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 2001; 358: 1134–1140. OS
  • Martinez‐Perez M. E., Hughes A. D., Stanton A. V., Thom S. A., Chapman N., Bharath A. A., Parker K. H. Retinal vascular tree morphology: a semi‐automatic quantification. IEEE Trans Biomed Eng 2002; 49: 912–917
  • Hughes A. D., Martinez‐Perez E., Jabbar A. S., Hassan A., Witt N. W., Mistry P. D., Chapman N., Stanton A. V., Beevers G., Pedrinelli R., Parker K. H., Thom S. A. Quantification of topological changes in retinal vascular architecture in essential and malignant hypertension. J Hypertens 2006; 24: 889–894
  • Antonios T. F., Singer D. R., Markandu N. D., Mortimer P. S., MacGregor G. A. Rarefaction of skin capillaries in borderline essential hypertension suggests an early structural abnormality. Hypertension 1999; 34: 655–658. OS
  • Noon J. P., Walker B. R., Webb D. J., Shore A. C., Holton D. W., Edwards H. V., Watt G. C. Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest 1997; 99: 1873–1879. OS
  • Price T. R., Manolio T. A., Kronmal R. A., Kittner S. J., Yue N. C., Robbins J., Anton‐Culver H., O'Leary D. H. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community‐dwelling older adults: the Cardiovascular Health Study. Stroke 1997; 28: 1158–1164. OS
  • Liao D., Cooper L., Cai J., Toole J. F., Bryan N. R., Hutchinson R. G., Tyroler H. A. Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control: The ARIC Study. Stroke 1996; 27: 2262–2270. OS
  • Vermeer S. E., Koudstaal P. J., Oudkerk M., Hofman A., Breteler M. M. Prevalence and risk factors of silent brain infarcts in the population‐based Rotterdam Scan Study. Stroke 2002; 33: 21–25. OS
  • Longstreth W. T., Jr., Manolio T. A., Arnold A., Burke G. L., Bryan N., Jungreis C. A., Enright P. L., O'Leary D., Fried L. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke 1996; 27: 1274–1282. OS
  • Prins N. D., van Dijk E. J., den Heijer T., Vermeer S. E., Koudstaal P. J., Oudkerk M., Hofman A., Breteler M. M. Cerebral white matter lesions and the risk of dementia. Arch Neurol 2004; 61: 1531–1534. OS
  • Vermeer S. E., Hollander M., van Dijk E. J., Hofman A., Koudstaal P. J., Breteler M. M., Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2000; 34: 1126–1129. OS
  • Skoog I., Lernfelt B., Landahl S., Palmertz B., Andreasson L. A., Nilsson L., Persson G., Oden A., Svanborg A. 15‐year longitudinal study of blood pressure dementia. Lancet 1996; 347: 1141–1145. OS
  • Kilander L., Nyman H., Boberg M., Hansson L., Lithell H. Hypertension is related to cognitive impairment: A 20‐year follow‐up of 999 men. Hypertension 1998; 31: 780–786. OS
  • Launer L. J., Masaki K., Petrovitch H., Foley D., Havlik R. J. The association between midlife blood pressure levels and late‐life cognitive function. The Honolulu‐Asia Aging Study. JAMA 1995; 274: 1846–1851. OS
  • Mancia G. Role of outcome trials in providing information on antihypertensive treatment: importance and limitations. Am J Hypertens 2006; 19: 1–7. RV
  • Zanchetti A. Evidence‐based medicine in hypertension: what type of evidence?. J Hypertens 2005; 23: 1113–1120. RV
  • Forette F., Seux M. L., Staessen J. A., Thijs L., Babarskiene M. R., Babeanu S., Bossini A., Fagard R., Gil‐Extremera B., Laks T., Kobalava Z., Sarti C., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y., Birkenhager W. H., Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst‐Eur) study. Arch Intern Med 2002; 162: 2046–2052. CT
  • Forette F., Seux M. L., Staessen J. A., Thijs L., Babarskiene M. R., Babeanu S., Bossini A., Fagard R., Gil‐Extremera B., Laks T., Kobalava Z., Sarti C., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y., Birkenhager W. H., Systolic Hypertension in Europe Investigators. Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22: 847–857. CT
  • Mann J. F., Gerstein H. C., Pogue J., Bosch J., Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–636. CT
  • Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 115 through 129 mmHg. JAMA 1967; 202: 1026–1034. RT
  • Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Medical Research Council. BMJ 1985; 291: 97–104. RT
  • SHEP Collaborative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264. RT
  • Dahlof B., Lindholm L. H., Hansson L., Schersten B., Ekbom T., Wester P. O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP‐Hypertension). Lancet 1991; 338: 1281–1285. RT
  • Amery A., Birkenhager W., Brixko P., Bulpitt C., Clement D., Deruyttere M., De Schaepdryver A., Dollery C., Fagard R., Forette F. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349–1354. RT
  • PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure‐lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–1041. RT
  • Staessen J. A., Fagard R., Thijs L., Celis H., Arabidze G. G., Birkenhager W. H., Bulpitt C. J., de Leeuw P. W., Dollery C. T., Fletcher A. E., Forette F., Leonetti G., Nachev C., O'Brien E. T., Rosenfeld J., Rodicio J. L., Tuomilehto J., Zanchetti A., for the Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Randomised double‐blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757–764. RT
  • Gong L., Zhang W., Zhu Y., Zhu J., Kong D., Page V., Ghadirian P., LeLorier J., Hamet P. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 16: 1237–1245. CT
  • Liu L., Wang J. L., Gong L., Liu G., Staessen J. A., For the Syst‐China Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens 1998; 16: 1823–1829. CT
  • Coope J., Warrender T. S. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J 1986; 293: 1145–1151. RT
  • MRC Working Party. Medical Research Council trial of treatmeant of hypertension in older adults: principal results. Br Med J 1992; 304: 405–412. RT
  • PATS Collaborative Group. Post‐stroke antihypertensive treatment study. Chin Med J 1995; 108: 710–717. RT
  • Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med 1980; 69: 725–732. RT
  • Management Committee. The Australian therapeutic trial in mild hypertension. Lancet 1980; 1: 1261–1267. RT
  • Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood‐pressure‐lowering regimens on major cardiovascular events: results of prospectively‐designed overviews of randomised trials. Lancet 2003; 362: 1527–1535. MA
  • Staessen J. A., Wang J. G., Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J Hypertens 2003; 21: 1055–1076. MA
  • Staessen J. A., Gasowski J., Wang J. G., Thijs L., Den Hond E., Boissel J. P., Coope J., Ekbom T., Gueyffier F., Liu L., Kerlikowske K., Pocock S., Fagard R. H. Risks of untreated and treated isolated systolic hypertension in the elderly: meta‐analysis of outcome trials. Lancet 2000; 355: 865–872. MA
  • Gueyffier F., Boutitie F., Boissel J. P., Pocock S., Coope J., Cutler J., Ekbom T., Fagard R., Friedman L., Perry M., Prineas R., Schron E. The effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. Results from a meta‐analysis of individual patient data randomised controlled trials. Ann Intern Med 1997; 126: 761–767. MA
  • Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure‐lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410–1419. MA
  • Bradley H. A., Wiysonge C. S., Volmink J. A., Mayosi B. M., Opie L. H. How strong is the evidence for use of beta‐blockers as first‐line therapy for hypertension? Systematic review and meta‐analysis. J Hypertens 2006; 24: 2131–2141. MA
  • Neal B., MacMahon S., Chapman N., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood‐pressure‐lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955–1964
  • Brewster L. M., van Montfrans G. A., Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med 2004; 141: 614–627. MA
  • The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin‐converting‐enzyme inhibitor, ramipril, on cardiovascular events in high‐risk patients. N Engl J Med 2000; 342: 145–153. RT
  • Liu L., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A., FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long‐term placebo‐controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23: 2157–2172. RT
  • The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double‐blind, placebo‐controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782–788. RT
  • Poole‐Wilson P. A., Lubsen J., Kirwan B. A., van Dalen F. J., Wagener G., Danchin N., Just H., Fox K. A., Pocock S. J., Clayton T. C., Motro M., Parker J. D., Bourassa M. G., Dart A. M., Hildebrandt P., Hjalmarson A., Kragten J. A., Molhoek G. P., Otterstad J. E., Seabra‐Gomes R., Soler‐Soler J., Weber S. A Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators. Effect of long‐acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–857. RT
  • Lubsen J., Wagener G., Kirwan B. A., de Brouwer S., Poole‐Wilson P. A. ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators. Effect of long‐acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial. J Hypertens 2005; 23: 641–648. CT
  • Nissen S. E., Tuzcu E. M., Libby P., Thompson P. D., Ghali M., Garza D., Berman L., Shi H., Buebendorf E., Topol E. J., CAMELOT Investigators. Effect of antihypertensive agents on cardiorprovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–2225. RT
  • The PEACE trial investigators. Angiotensin‐converting‐enzyme inhibition in stable coronary artery disease. New Engl J Med 2004; 351: 2058–2068. RT
  • Lithell H., Hansson L., Skoog I., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A., SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double‐blind intervention trial. J Hypertens 2003; 21: 875–886. RT
  • Brenner B. M., Cooper M. E., de Zeeuw D., Keane W. F., Mitch W. E., Parving H. H., Remuzzi G., Snapinn S. M., Zhang Z., Shahinfar S., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869. RT
  • Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., Ritz E., Atkins R. C., Rohde R., Raz I., Collaborative Study Group. Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860. RT
  • Pourdjabbar A. M., Lapointe N., Rouleau J‐L. Angiotensin receptor blockers: Powerful evidence with cardiovascular outcomes?. Can J Cardiol 2002; 18((Suppl A))7A–14A. MA
  • Hansson L., Zanchetti A., Carruthers S. G., Dahlof B., Elmfeldt D., Julius S., Menard J., Rahn K. H., Wedel H., Westerling S. Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762. RT
  • Hypertension Detection, Follow‐up Program. The effect of treatment on mortality in ‘mild’ hypertension: results of the Hypertension Detection, Follow‐up Program. N Engl J Med 1982; 307: 976–980. RT
  • Hansson L., Lindholm L. H., Niskanen L., Lanke J., Hedner T., Niklason A., Luomanmaki K., Dahlof B., de Faire U., Morlin C., Karlberg B. E., Wester P. O., Bjorck J. E. Effect of angiotensin‐converting‐enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616. RT
  • Hansson L., Lindholm L. H., Ekbom T., Dahlof B., Lanke J., Schersten B., Wester P. O., Hedner T., de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension‐2 study. Lancet 1999; 354: 175–1756. RT
  • Hansson L., Hedner T., Lund‐Johansen P., Kjeldsen S. E., Lindholm L. H., Syvertsen J. O., Lanke J., de Faire U., Dahlof B., Karlberg B. E. Randomised trial of effects of calcium antagonists compared with diuretics and beta‐blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359–365. RT
  • UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascularand microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–720. RT
  • Agodoa L. Y., Appel L., Bakris G. L., Beck G., Bourgoignie J., Briggs J. P., Charleston J., Cheek D., Cleveland W., Douglas J. G., Douglas M., Dowie D., Faulkner M., Gabriel A., Gassman J., Greene T., Hall Y., Hebert L., Hiremath L., Jamerson K., Johnson C. J., Kopple J., Kusek J., Lash J., Lea J., Lewis J. B., Lipkowitz M., Massry S., Middleton J., Miller E. R., 3rd., Norris K., O'Connor D., Ojo A., Phillips R. A., Pogue V., Rahman M., Randall O. S., Rostand S., Schulman G., Smith W., Thornley‐Brown D., Tisher C. C., Toto R. D., Wright J. T., Jr., Xu S., African American Study of Kidney Disease, Hypertension (AASK) Study Group. Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis. A Randomized Controlled Trial. JAMA 2001; 285: 2719–2728. RT
  • Wright J. T., Jr., Bakris G., Greene T., Agodoa L. Y., Appel L. J., Charleston J., Cheek D., Douglas‐Baltimore J. G., Gassman J., Glassock R., Hebert L., Jamerson K., Lewis J., Phillips R. A., Toto R. D., Middleton J. P., Rostand S. G., African American Study of Kidney Disease, Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA 2002; 288: 2421–2431. RT
  • Schrier R. W., Estacio R. O., Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and stroke. Kidney Int 2002; 61: 1086–1097. RT
  • Estacio R. O., Jeffers B. W., Hiatt W. R., Biggerstaff S. L., Gifford N., Schrier R. W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non‐insulin independent diabetes and hypertension. N Engl J Med 1998; 338: 645–652. RT
  • Brown M. J., Palmer C. R., Castaigne A., de Leeuw P. W., Mancia G., Rosenthal T., Ruilope L. M. Morbidity and mortality in patients randomised to double‐blind treatment with a long‐acting calcium‐channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–372. RT
  • The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high‐risk hypertensive patients randomized to angiotensin‐converting enzyme inhibitor or calcium channel blocker vs diuretic: The Anti hypertensive and Lipid‐Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997. RT
  • Black H. R., Elliott W. J., Grandits G., Grambsch P., Lucente T., White W. B., Neaton J. D., Grimm R. H., Jr., Hansson L., Lacourciere Y., Muller J., Sleight P., Weber M. A., Williams G., Wittes J., Zanchetti A., Anders R. J., CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) trial. JAMA 2003; 289: 2073–2082. RT
  • Malacco E., Mancia G., Rappelli A., Menotti A., Zuccaro M. S., Coppini A., SHELL Investigators. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press 2003; 12: 160–167. RT
  • NICS Study Group. Randomized double‐blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. Hypertension 1999; 34: 1129–1133. RT
  • Yui Y., Sumiyoshi T., Kodama K., Hirayama A., Nonogi H., Kanmatsuse K., Origasa H., Iimura O., Ishii M., Saruta T., Arakawa K., Hosoda S., Kawai C., Japan Multicenter Investigation for Cardiovascular Diseases‐B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases‐B (JMIC‐B) randomized trial. Hypertens Res 2004; 27: 181–191. RT
  • Wing L. M., Reid C. M., Ryan P., Beilin L. J., Brown M. A., Jennings G. L., Johnston C. I., McNeil J. J., Macdonald G. J., Marley J. E., Morgan T. O., West M. J., Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin‐converting‐enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–592. RT
  • Verdecchia P., Reboldi G., Angeli F., Gattobigio R., Bentivoglio M., Thijs L., Staessen J. A., Porcellati C. Angiotensin‐converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386–392
  • Blood Pressure Lowering Treatment Trialists' Collaboration. Blood pressure dependent and independent effects of agents that inhibit the renin‐angiotensin system. J Hypertens 2007; 25: 951–958. MA
  • Dahlof B., Sever P. S., Poulter N. R., Wedel H., Beevers D. G., Caulfield M., Collins R., Kjeldsen S. E., Kristinsson A., McInnes G. T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendo‐flumethiazide as required, in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Blood Pressure Lowering Arm (ASCOT‐BPLA): a multicentre randomized controlled trial. Lancet 2005; 366: 895–906. RT
  • Pepine C. J., Handberg E. M., Cooper‐DeHoff R. M., Marks R. G., Kowey P., Messerli F. H., Mancia G., Cangiano J. L., Garcia‐Barreto D., Keltai M., Erdine S., Bristol H. A., Kolb H. R., Bakris G. L., Cohen J. D., Parmley W. W., INVEST Investigators. A calcium antagonist vs a non‐calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil‐Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–2816. RT
  • Dahlof B., Devereux R. B., Kjeldsen S. E., Julius S., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe‐Pedersen O., Lindholm L. H., Nieminen M. S., Omvik P., Oparil S., Wedel H., LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003. RT
  • Schrader J., Luders S., Kulschewski A., Hammersen F., Plate K., Berger J., Zidek W., Dominiak P., Diener HCMOSES Study Group. Morbidity and Mortality After Stroke. Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36: 1218–1226. RT
  • Mochizuki S., Dahlof B., Shimizu M., Ikewaki K., Yoshikawa M., Taniguchi I., Ohta M., Yamada T., Ogawa K., Kanae K., Kawai M., Seki S., Okazaki F., Taniguchi M., Yoshida S., Tajima N for the Jikei Heart Study group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open‐label, blinded endpoint morbidity‐mortality study. Lancet 2007; 369: 1431–1439. RT
  • Julius S., Kjeldsen S. E., Weber M., Brunner H. R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G. T., Mitchell L., Plat F., Schork A., Smith B., Zanchetti A. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031. RT
  • Verma S., Strauss M. Angiotensin receptor blockers and myocardial infarction. Br Med J 2004; 329: 1248–1249. RV
  • Volpe M., Mancia G., Trimarco B. Angiotensin receptor blockers and myocardial infarction: the importance of dosage. J Hypertens 2006; 24: 1681–1682. RV
  • Verdecchia P., Angeli F., Gattobigio R., Reboldi G. P. Do angiotensin II receptor blockers increase the risk of myocardial infarction?. Eur Heart J 2005; 26: 2381–2386. MA
  • Teo K., Yusuf S., Sleight P., Anderson C., Mookadam F., Ramos B., Hilbrich L., Pogue J., Schumacher H., ONTARGET/TRANSCEND Investigators. Rationale, design, baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, their combination in high‐risk patients: the Ongoing Telmisartan Alone, in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52–61. RT
  • Dickstein K., Kjekshus J., OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high‐risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002; 360: 752–760. RT
  • Pfeffer M. A., McMurray J. J., Velazquez E. J., Rouleau J. L., Kober L., Maggioni A. P., Solomon S. D., Swedberg K., Van de Werf F., White H., Leimberger J. D., Henis M., Edwards S., Zelenkofske S., Sellers M. A., Califf R. M. Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–1896. RT
  • Pitt B., Poole‐Wilson P. A., Segal R., Martinez F. A., Dickstein K., Camm A. J., Konstam M. A., Riegger G., Klinger G. H., Neaton J., Sharma D., Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial‐the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–1587. RT
  • Lindholm L. H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta‐analysis. Lancet 2005; 366: 1545–1553. MA
  • Hypertension: management of hypertension in adults in primary care NICE/BHS. GL. June 2006. wwww.nice.org.uk/CG034nice.org.uk/CG034.
  • McInnes G. T., Kjeldsen S. E. Never mind the quality, feel the width–ALLHAT revisited. Blood Press 2004; 13: 330–334. RV
  • Wright J. T., Jr., Dunn J. K., Cutler J. A., Davis B. R., Cushman W. C., Ford C. E., Haywood L. J., Leenen F. H., Margolis K. L., Papademetriou V., Probstfield J. L., Whelton P. K., Habib G. B., ALLHAT Collaborative Research Group. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293: 1595–1608. CT
  • Cuspidi C., Muiesan M. L., Valagussa L., Salvetti M., Di Biagio C., Agabiti‐Rosei E., Magnani B., Zanchetti A. CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–2300. RT
  • Jennings G. L., McMullen J. R. Left ventricular hypertrophy. Beyond the image and defining human cardiac phenotype in hypertension. J Hypertens 2007, in press. RV
  • Klingbeil A. U., Schneider M., Martus P., Messerli F. H., Schmieder R. E. A meta‐analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41–46. MA
  • Terpstra W. F., May J. F., Smit A. J., de Graeff P. A., Havinga T. K., van den Veur E., Schuurman F. H., Meyboom‐de Jong B., Crijns H. J. Long‐term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens 2001; 19: 303–309. RT
  • Devereux R. B., Palmieri V., Sharpe N., De Quattro V., Bella J. N., de Simone G., Walker J. F., Hahn R. T., Dahlof B. Effects of once‐daily angiotensin‐converting enzyme inhibition and calcium channel blockade‐based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension. The Prospective Randomized Enalapril Study Evaluating Regression of Ventricular Enlargement (PRESERVE) trial. Circulation 2001; 104: 1248–1254. RT
  • Zanchetti A., Ruilope L. M., Cuspidi C., Macca G., Verschuren J., Kerselaers W. Comparative effects of the ACE inhibitor fosinopril and the calcium antagonist amlodipine on left ventricular hypertrophy and urinary albumin excretion in hypertensive patients. Results of FOAM, a multicenter European study. J Hypertens 2001; 19((Suppl 2))S92. (abstract). RT
  • Agabiti‐Rosei E., Trimarco B., Muiesan M. L., Reid J., Salvetti A., Tang R., Hennig M., Baurecht H., Parati G., Mancia G., Zanchetti A., ELSA Echocardiographic Substudy Group. Cardiac structural and functional changes during long‐term antihypertensive treatment with lacidipine and atenolol in the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2005; 23: 1091–1098. CT
  • Thurmann P. A., Kenedi P., Schmidt A., Harder S., Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998; 98: 2037–2042. RT
  • Malmqvist K., Kahan T., Edner M., Held C., Hagg A., Lind L., Muller‐Brunotte R., Nystrom F., Ohman K. P., Osbakken M. D., Ostergern J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167–1176. RT
  • Dahlof B., Zanchetti A., Diez J., Nicholls M. G., Yu C. M., Barrios V., Aurup P., Smith R. D., Johansson M., For the REGAAL Study Investigators. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy. J Hypertens 2002; 20: 1855–1864. RT
  • Devereux R. B., Dahlof B., Gerdts E., Boman K., Nieminen M. S., Papademetriou V., Rokkedal J., Harris K. E., Edelman J. M., Wachtell K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110: 1456–1462. RT
  • De Luca N., Mallion J. M., O'Rourke M. F., O'Brien E., Rahn K. H., Trimarco B., Romero R., De Leeuw P. W., Hitzenberger G., Battegay E., Duprez D., Sever P., Safar M. E. Regression of left ventricular mass in hypertensive patients treated with perindopril/indapamide as a first‐line combination: the REASON echocardiography study. Am J Hypertens 2004; 17: 660–667. RT
  • Dahlof B., Gosse P., Gueret P., Dubourg O., de Simone G., Schmieder R., Karpov Y., Garcia‐Puig J., Matos L., De Leeuw P. W., Degaute J. P., Magometschnigg D., The PICXEL Investigators. Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens 2005; 23: 2063–2070. RT
  • De Luca N., Asmar R. G., London G. M., O'Rourke M. F., Safar M. E., REASON Project Investigators. Selective reduction of cardiac mass and central blood pressure on low‐dose combination perindopril/indapamide in hypertensive subjects. J Hypertens 2004; 22: 1623–1630. RT
  • Pitt B., Reichek N., Willenbrock R., Zannad F., Phillips R. A., Roniker B., Kleiman J., Krause S., Burns D., Williams G. H. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E‐left ventricular hypertrophy study. Circulation 2003; 108: 1831–1838. RT
  • Galzerano D., Tammaro P., del Viscovo L., Lama D., Galzerano A., Breglio R., Tuccillo B., Paolisso G., Capogrosso P. Three‐dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study. Am J Hypertens 2005; 18: 1563–1569. RT
  • Gosse P., Sheridan D. J., Zannad F., Dubourg O., Gueret P., Karpov Y., de Leeuw P. W., Palma‐Gamiz J. L., Pessina A., Motz W., Degaute J. P., Chastang C. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg; the LIVE study. J Hypertens 2000; 18: 1465–1475. RT
  • Muiesan M. L., Salvetti M., Rizzoni D., Castellano M., Donato F. Agabiti Rosei E. Association of change in left ventricular mass with prognosis during long‐term antihypertensive treatment. J Hypertens 1995; 13: 1091–1095. OS
  • Koren M. J., Ulin R. J., Koren A. T., Laragh J. H., Devereux R. B. Left ventricular mass change during treatment and outcome in patients with essential hypertension. Am J Hypertens 2002; 15: 1021–1028. OS
  • Cuspidi C., Ciulla M., Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 2006; 21: 20–23. RV
  • Ciulla M. M., Paliotti R., Esposito A., Cuspidi C., Muiesan M. L., Salvetti M., Agabiti‐Rosei E., Magrini F., Zanchetti A. Effects of the angiotension receptor antagonist candesartan and the ACE inhibitor Enalapril on ultrasound markers of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy. J Hypertens 2005; 23((Suppl 2))S381. (abstract). RT
  • Christensen M. K., Olsen M. H., Wachtell K., Tuxen C., Fossum E., Bang L. E., Wiinberg N., Devereux R. B., Kjeldsen S. E., Hildebrandt P., Rokkedal J., Ibsen H. Does long‐term losartan‐ vs atenolol‐based antihypertensive treatment influence collagen markers differently in hypertensive patients? A LIFE substudy. Blood Press 2006; 15: 198–206. CT
  • Olsen M. H., Wachtell K., Tuxen C., Fossum E., Bang L. E., Hall C., Ibsen H., Rokkedal J., Devereux R. B., Hildebrandt P. N‐terminal pro‐brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 2004; 22: 1597–1604. OS
  • Okin P. M., Devereux R. B., Jern S., Kjeldsen S. E., Julius S., Nieminen M. S., Snapinn S., Harris K. E., Aurup P., Edelman J. M., Dahlof B. Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention For Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003; 108: 684–690. RT
  • Schneider M. P., Klingbeil A. U., Delles C., Ludwig M., Kolloch R. E., Krekler M., Stumpe K. O., Schmieder R. E. Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the CardioVascular Irbesartan Project. Hypertension 2004; 44: 61–66. RT
  • Havranek E. P., Esler A., Estacio R. O., Mehler P. S., Schrier R. W., Appropriate Blood Pressure Control in Diabetes Trial. Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am Heart J 2003; 145: 993–998. RT
  • Muller‐Brunotte R., Edner M., Malmqvist K., Kahan T. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J Hypertens 2005; 23: 633–640. RT
  • Cuspidi C., Meani S., Valerio C., Fusi V., Catini E., Sala C., Zanchetti A. Ambulatory blood pressure, target organ damage and left atrial size in never‐treated essential hypertensive individuals. J Hypertens 2005; 23: 1589–1595. OS
  • Gerdts E., Wachtell K., Omvik P., Otterstad J. E., Oikarinen L., Boman K., Dahlof B., Devereux R. B. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension 2007; 49: 311–316. OS
  • Aksnes T. A., Flaa A., Strand A., Kjeldsen S. E. Prevention of new‐onset atrial fibrillation and its predictors with angiotensin II‐receptor blockers in the treatment of hypertension and heart failure. J Hypertens 2007; 25: 15–23. RV
  • Wachtell K., Lehto M., Gerdts E., Olsen M. H., Hornestam B., Dahlof B., Ibsen H., Julius S., Kjeldsen S. E., Lindholm L. H., Nieminen M. S., Devereux R. B. Angiotensin II receptor blockade reduces new‐onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712–719. RT
  • Schmieder R., Kjeldsen S. E., Julius S., McInnes G. T., Zanchetti A., Hua T. Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade: the VALUE‐trial. J Hypertens 2006; 24: S3 (abstract). RT
  • Vermes E., Tardif J. C., Bourassa M. G., Racine N., Levesque S., White M., Guerra P. G., Ducharme A. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926–2931. RT
  • Ducharme A., Swedberg K., Pfeffer M. A., Cohen‐Solal A., Granger C. B., Maggioni A. P., Michelson E. L., McMurray J. J., Olsson L., Rouleau J. L., Young J. B., Olofsson B., Puu M., Yusuf S., CHARM Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86–92. RT
  • Maggioni A. P., Latini R., Carson P. E., Singh S. N., Barlera S., Glazer R., Masson S., Cere E., Tognoni G., Cohn J. N., Val‐HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val‐HeFT). Am Heart J 2005; 149: 548–557. RT
  • Okin P. M., Wachtell K., Devereux R. B., Harris K. E., Jern S., Kjeldsen S. E., Julius S., Lindholm L. H., Nieminen M. S., Edelman J. M., Hille D. A., Dahlof B. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new‐onset atrial fibrillation in patients with hypertension. JAMA 2006; 296: 1242–1248. OS
  • Madrid A. H., Bueno M. G., Rebollo J. M., Marin I., Pena G., Bernal E., Rodriguez A., Cano L., Cano J. M., Cabeza P., Moro C. Use of irbesartan to maintain sinus rhythm in patients with long‐lasting persistent atrial fibrillation: a prospective, randomized study. Circulation 2002; 106: 331–336. RT
  • Fogari R., Mugellini A., Destro M., Corradi L., Zoppi A., Fogari E., Rinaldi A. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006; 47: 46–50. RT
  • Disertori M., Latini R., Maggioni A. P., Delise P., Di Pasquale G., Franzosi M. G., Staszewsky L., Tognoni G., on behalf of the GISSI‐AF Investigators. Rationale, design of the GISSI‐Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT 1‐receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med 2006; 7: 29–38. RT
  • Wang J. G., Staessen J. A., Li Y., Van Bortel L. M., Nawrot T., Fagard R., Messerli F. H., Safar M. Carotid intima‐media thickness and antihypertensive reatment: a meta‐analysis of randomized controlled trials. Stroke 2006; 37: 1933–1940. MA
  • MacMahon S., Sharpe N., Gamble G., Clague A., Mhurchu C. N., Clark T., Hart H., Scott J., White H. Randomized, placebo‐controlled trial of the angiotensin‐converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART‐2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol 2000; 36: 438–443. RT
  • Asselbergs F. W., van Roon A. R., Hillege H. L., de Jong R. E., Gans R. O. B., Smit A. J., van Gilst W. H., on behalf of the PREVEND IT Investigators PREVEND IT Investigators. Effects of fosinopril and pravastatin on carotid intima‐media thickness in subjects with increased albuminuria. Stroke 2005; 36: 649–653. RT
  • Hedblad B., Wikstrand J., Janzon L., Wedel H., Berglund G. Low‐dose metoprolol CR/XL and fluvastatin slow progression of carotid intima‐media thickness: Main results from the Beta‐Blocker Cholesterol‐Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721–1726. RT
  • Zanchetti A., Crepaldi G., Bond M. G., Gallus G., Veglia F., Mancia G., Ventura A., Baggio G., Sampietri L., Rubba P., Sperti G., Magni A., on behalf of PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS‐a randomized double‐blind trial. Stroke 2004; 35: 2807–2812. RT
  • Simon A., Gariepy J., Moyse D., Levenson J. Differential effects of nifedipine and co‐amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949–2954. CT
  • Terpstra W. F., May J. F., Smit A. J., Graeff P. A., Meyboom‐de Jong B., Crijns H. J. Effects of amlodipine and lisinopril on intima‐media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 2004; 22: 1309–1316. RT
  • Pitt B., Byington R. P., Furberg C. D., Hunninghake D. B., Mancini G. B. J., Miller M. E., Riley W. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503–1510. RT
  • Lonn E. M., Yusuf S., Dzavik V., Doris C. I., Yi Q., Smith S., Moore‐Cox A., Bosch J., Riley W. A., Teo K. K. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E SECURE). Circulation 2001; 103: 919–925. CT
  • Borhani N. O., Mercuri M., Borhani P. A., Buckalew V. M., Canossa‐Terris M., Carr A. A., Kappagoda T., Rocco M. V., Schnaper H. W., Sowers J. R., Bond M. G. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785–791. RT
  • Ciulla M. M., Paliotti R., Ferrero S., Vandoni P., Magrini F., Zanchetti A. Assessment of carotid plaque composition in hypertensive patients by ultrasonic tissue characterization: a validation study. J Hypertens 2002; 20: 1589–1596
  • Paliotti R., Ciulla M. M., Hennig M., Tang R., Bond M. G., Mancia G., Magrini F., Zanchetti A. Carotid wall composition in hypertensive patients after 4‐year treatment with lacidipine or atenolol: an echoreflectivity study. J Hypertens 2005; 23: 1203–1209. CT
  • Asmar R. Effect of antihypertensive agents on arterial stiffness as evaluated by pulse wave velocity: clinical implications. Am J Cardiovasc Drugs 2001; 1: 387–397. RV
  • Ichihara A., Hayashi M., Koura Y., Tada Y., Hirota N., Saruta T. Long‐term effects of intensive blood‐pressure lowering on arterial wall stiffness in hypertensive patients. Am J Hypertens 2003; 16: 959–965. OS
  • Asmar R. G., London G. M., O'Rourke M. E., Safar M. E., REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very‐low‐dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001; 38: 922–926. RT
  • Rajzer M., Klocek M., Kawecka‐Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild‐to‐moderate arterial hypertension. Am J Hypertens 2003; 16: 439–444. RT
  • Munakata M., Nagasaki A., Nunokawa T., Sakuma T., Kato H., Yoshinaga K., Toyota T. Effects of valsartan and nifedipine coat‐core on systemic arterial stiffness in hypertensive patients. Am J Hypertens 2004; 17: 1050–1055. RT
  • Dhakam Z., McEniery C. M., Yasmin, Cockcroft J. R., Brown M. J., Wilkinson I. B. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens 2006; 19: 214–219. RT
  • Staessen J. A., Richart T., Birkenhager W. H. Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. Hypertension 2007; 49: 389–400. RV
  • Dufouil C., Chalmers J., Coskun O., Besancon V., Bousser M. G., Guillon P., MacMahon S., Mazoyer B., Neal B., Woodward M., Tzourio‐Mazoyer N., Tzourio C., PROGRESS MRI Substudy Investigators. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112: 1644–1650. CT
  • Birns J., Morris R., Donaldson N., Kalra L. The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J Hypertens 2006; 24: 1907–1914. MA
  • Forette F., Seux M. L., Staessen J. A., Thijs L., Birkenhager W. H., Babarskiene M. R., Babeanu S., Bossini A., Gil‐Extremera B., Girerd X., Laks T., Lilov E., Moisseyev V., Tuomilehto J., Vanhanen H., Webster J., Yodfat Y., Fagard R. Prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst‐Eur) study. Lancet 1998; 352: 1347–1351. RT
  • Skoog I., Lithell H., Hansson L., Elmfeldt D., Hofman A., Olofsson B., Trenkwalder P., Zanchetti A., SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005; 18: 1052–1059. RT
  • Goldstein G., Materson B. J., Cushman W. C., Reda D. J., Freis E. D., Ramirez E. A., Talmers F. N., White T. J., Nunn S., Chapman R. H. Treatment of hypertension in the elderly: II. Cognitive and behavioral function. Results of a Department of Veterans Affairs Cooperative Study. Hypertension 1990; 15: 361–369. RT
  • McCorvey E., Jr., Wright J. T., Jr., Culbert J. P., McKenney J. M., Proctor J. D., Annett M. P. Effect of hydrochlorothiazide, enalapril, and propranolol on quality of life and cognitive and motor function in hypertensive patients. Clin Pharm 1993; 12: 300–305. RT
  • Leonetti G., Salvetti A. Effects of cilazapril and nitrendipine on blood pressure, mood, sleep, and cognitive function in elderly hypertensive patients: an Italian multicenter study. J Cardiovasc Pharmacol 1994; 24((Suppl 3))S73–S77RT
  • Starr J. M., Whalley L. J., Deary I. J. The effects of antihypertensive treatment on cognitive function: results from the HOPE study. J Am GeriatrSoc 1996; 44: 411–415. CT
  • Fogari R., Mugellini A., Zoppi A., Marasi G., Pasotti C., Poletti L., Rinaldi A., Preti P. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004; 59: 863–868. RT
  • Prince M. J., Bird A. S., Blizard R. A., Mann A. H. Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's trial of hypertension in older adults. BMJ 1996; 312: 801–805. CT
  • Casas J. P., Chua W., Loukogeorgakis S., Vallance P., Smeeth L., Hingorani A. D., MacAllister R. J. Effect of inhibitors of the renin‐angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta‐analysis. Lancet 2005; 366: 2026–2033. MA
  • De Zeeuw D., Lewis E. J., Remuzzi G., Brenner B. M., Cooper M. E. Renoprotective effects of renin‐angiotensin‐system inhibitors. Lancet 2006; 367: 899–900
  • Mann J. F., Ritz E., Kunz R. Renoprotective effects of renin‐angiotensin‐system inhibitors. Lancet 2006; 367: 900
  • Zanchetti A., Ruilope L. M. Antihypertensive treatment in patients with type‐2 diabetes mellitus: what guidance from recent controlled randomized trials?. J Hypertens 2002; 20: 2099–2110. RV
  • Karalliedde J., Viberti G. Evidence for renoprotection by blockade of the renin‐angiotensin‐aldosterone system in hypertension and diabetes. J Hum Hypertens 2006; 20: 239–253. RT
  • Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension, antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43((5 Suppl 1))S1–290. GL
  • Levey A. S., Greene T., Beck G. J., Caggiula A. W., Kusek J. W., Hunsicker L. G., Klahr S. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 1999; 10: 2426–2439. CT
  • Estacio R. O., Jeffers B. W., Gifford N., Schrier R. W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23((Suppl 2))B54–B64. RT
  • Estacio R. O., Coll J. R., Tran Z. V., Schrier R. W. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens 2006; 19: 1241–1248. RT
  • Ruggenenti P., Perna A., Loriga G., Ganeva M., Ene‐Iordache B., Turturro M., Lesti M., Perticucci E., Chakarski I. N., Leonardis D., Garini G., Sessa A., Basile C., Alpa M., Scanziani R., Sorba G., Zoccali C., Remuzzi G., REIN‐2 Study Group REIN‐2 Study Group. Blood‐pressure control for renoprotection in patients with non‐diabetic chronic renal disease (REIN‐2): multicentre, randomised controlled trial. Lancet 2005; 365: 939–946. RT
  • Pohl M. A., Blumenthal S., Cordonnier D. J., De Alvaro F., Deferrari G., Eisner G., Esmatjes E., Gilbert R. E., Hunsicker L. G., de Faria J. B., Mangili R., Moore J., Jr., Reisin E., Ritz E., Schernthaner G., Spitalewitz S., Tindall H., Rodby R. A., Lewis E. J. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol 2005; 16: 3027–3037. CT
  • Jafar T. H., Stark P. C., Schmid C. H., Landa M., Maschio G., de Jong P. E., de Zeeuw D., Shahinfar S., Toto R., Levey A. S., AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin‐converting enzyme inhibition: a patient‐level meta‐analysis. Ann Intern Med 2003; 139: 244–252. MA
  • UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascularand microvascular complications in Type 2 diabetes. UKPDS38. BMJ 1998; 317: 703–713. RT
  • Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO‐HOPE substudy. Lancet 2000; 355: 253–259. RT
  • Adler A. I., Stratton I. M., Neil H. A., Yudkin J. S., Matthews D. R., Cull C. A., Wright A. D., Turner R. C., Holman R. R. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. Br Med J 2000; 321: 412–429. OS
  • Randomised placebo‐controlled trial of effect of ramipril on decline in glomerular filtration rate risk of terminal renal failure in proteinuric non‐diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857–1863. RT
  • Mann J. F., Gerstein H. C., Yi Q. L., Franke J., Lonn E. M., Hoogwerf B. J., Rashkow A., Yusuf S., HOPE Investigators. Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 2003; 42: 936–942. RT
  • Ruggenenti P., Fassi A., Ilieva A. P., Bruno S., Iliev I. P., Brusegan V., Rubis N., Gherardi G., Arnoldi F., Ganeva M., Ene‐Iordache B., Gaspari F., Perna A., Bossi A., Trevisan R., Dodesini A. R., Remuzzi G., Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–1951. RT
  • Mogensen C. E., Viberti G., Halimi S., Ritz E., Ruilope L., Jermendy G., Widimsky J., Sareli P., Taton J., Rull J., Erdogan G., De Leeuw P. W., Ribeiro A., Sanchez R., Mechmeche R., Nolan J., Sirotiakova J., Hamani A., Scheen A., Hess B., Luger A., Thomas S. M., Preterax in Albuminuria Regression (PREMIER) Study Group. Effect of low‐dose perindopril/indapamide on albuminuria in diabetes: Preterax in albuminuria regression: PREMIER. Hypertension 2003; 41: 1063–1071. RT
  • Lewis E. J., Hunsicker L. G., Bain R. P., Rohde R. D. The effect of angiotensin‐converting‐enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456–1462. RT
  • Parving H‐H., Lehnert H., Brochner‐Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878. RT
  • Schjoedt K. J., Rossing K., Juhl T. R., Boomsma F., Tarnow L., Rossing P., Parving H. H. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536–542. RT
  • Voyaki S. M., Staessen J. A., Thijs L., Wang J. G., Efstratopoulos A. D., Birkenhager W. H., de Leeuw P. W., Leonetti G., Nachev C., Rodicio J. L., Tuomilehto J., Fagard R., Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Follow‐up of renal function in treated and untreated older patients with isolated systolic hypertension. Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. J Hypertens 2001; 19: 511–519. RT
  • Rahman M., Pressel S., Davis B. R., Nwachuku C., Wright J. T., Jr., Whelton P. K., Barzilay J., Batuman V., Eckfeldt J. H., Farber M., Henriquez M., Kopyt N., Louis G. T., Saklayen M., Stanford C., Walworth C., Ward H., Wiegmann T. Renal outcomes in high‐risk hypertensive patients treated with an angiotensin‐converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid‐ Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165: 936–946. CT
  • Barnett A. H. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study 1. Acta Diabetol 2005; 42((Suppl 1))S42–S49. RT
  • Ibsen H., Olsen M. H., Wachtell K., Borch‐Johnsen K., Lindholm L. H., Mogensen C. E., Dahlof B., Snapinn S. M., Wan Y., Lyle P. A. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006; 29: 595–600. CT
  • Viberti G., Wheeldon N. M., MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure‐independent effect. Circulation 2002; 106: 672–678. RT
  • Vogt L., Navis G., Koster J., Manolis A. J., Reid J. L., de Zeeuw D., on behalf of the Angiotensin II Receptor Antagonist Telmisartan Micardis in Isolated Systolic Hypertension (ARAMIS) Study Group. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double‐blind, placebo‐controlled trial. J Hypertens 2005; 23: 2055–2061. RT
  • White W. B., Duprez D., St Hillaire R., Krause S., Roniker B., Kuse‐Hamilton J., Weber M. A. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 41: 1021–1026. RT
  • Dalla Vestra M., Pozza G., Mosca A., Grazioli V., Lapolla A., Fioretto P., Crepaldi G. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study. Diabetes Nutr Metab 2004; 17: 259–266. RT
  • Marre M., Puig J. G., Kokot F., Fernandez M., Jermendy G., Opie L., Moyseev V., Scheen A., Ionescu‐Tirgoviste C., Saldanha M. H., Halabe A., Williams B., Mion Junior D., Ruiz M., Hermansen K., Tuomilehto J., Finizola B., Gallois Y., Amouyel P., Ollivier J. P., Asmar R. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J Hypertens 2004; 22: 1613–1622. RT
  • Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., Ideura T. Combination treatment of angiotensin‐I I receptor blocker and angiotensin‐converting‐enzyme inhibitor in non‐diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117–124. RT
  • Kincaid‐Smith P., Fairley K., Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 2002; 17: 597–601. RT
  • Mogensen C. E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R. W., Cooper M. E. Randomised controlled trial of dual blockade of renin‐angiotensin system in patients with hypertension, microalbuminuria, and non‐insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000; 321: 1440–1444. RT
  • Andersen N. H., Poulsen P. L., Knudsen S. T., Poulsen S. H., Eiskjaer H., Hansen K. W., Helleberg K., Mogensen C. E. Long‐term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005; 28: 273–277. RT
  • MacKinnon M., Shurraw S., Akbari A., Knoll G. A., Jaffey J., Clark H. D. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8–20. MA
  • Rossing K., Schjoedt K. J., Jensen B. R., Boomsma F., Parving H. H. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005; 68: 1190–1198. RT
  • Schmieder R. E., Klingbeil A. U., Fleischmann E. H., Veelken R., Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double‐blind, randomized, prospective study. J Am Soc Nephrol 2005; 16: 3038–3045. RT
  • Kannel W. B., Wilson P. W., Zhang T. J. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991; 121: 1268–1273. OS
  • Stamler J., Vaccaro O., Neaton J. D., Wentworth D. Diabetes, other riskfactors, and 12‐yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444. CT
  • Mancia G., Grassi G., Zanchetti A. New‐onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10. RV
  • Norris K., Bourgoigne J., Gassman J., Hebert L., Middleton J., Phillips R. A., Randall O., Rostand S., Sherer S., Toto R. D., Wright J. T., Jr., Wang X., Greene T., Appel L. J., Lewis J., AASK Study Group. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) Trial. Am J Kidney Dis 2006; 48: 739–751. RT
  • Lindholm L. H., Persson M., Alaupovic P., Carlberg B., Svensson A., Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003; 21: 1563–1574. RT
  • Opie L. H., Schall R. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1453–1458. MA
  • Kostis J. B., Wilson A. C., Freudenberger R. S., Cosgrove N. M., Pressel S. L., Davis B. R., SHEP Collaborative Research Group. Long‐term effect of diuretic‐based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95: 29–35. CT
  • Elliott W. J., Meyer P. M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta‐analysis. Lancet 2007; 369: 201–207. MA
  • Domanski M., Norman J., Pitt B., Haigney M., Hanlon S., Peyster E., Studies of Left Ventricular Dysfunction. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42: 705–708. RT
  • Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., Wolffenbuttel B. H., Zinman B., HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001; 286: 1882–1885. RT
  • Pfeffer M. A., Swedberg K., Granger C. B., Held P., McMurray J. J., Michelson E. L., Olofsson B., Ostergren J., Yusuf S., Pocock S., CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM‐Overall programme. Lancet 2003; 362: 759–766. RT
  • DREAM Trial Investigators, Bosch J., Yusuf S., Gerstein H. C., Pogue J., Sheridan P., Dagenais G., Diaz R., Avezum A., Lanas F., Probstfield J., Fodor G., Holman R. R. Effect of ramipril on the incidence of diabetes. NEnglJMed 2006; 355: 1551–1562. RT
  • Howard B. V., Rodriguez B. L., Bennett P. H., Harris M. I., Hamman R., Kuller L. H., Pearson T. A., Wylie‐Rosett J. Prevention Conference VI: Diabetes and Cardiovascular disease: Writing Group I: epidemiology. Circulation 2002; 105: 132–137. RV
  • Alderman M. H., Cohen H., Madhavan S. Diabetes and cardiovascular events in hypertensive patients. Hypertension 1999; 33: 1130–1134. OS
  • Dunder K., Lind L., Zethelius B., Berglund L., Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. Br Med J 2003; 326: 681. OS
  • Eberly L. E., Cohen J. D., Prineas R., Yang L., Intervention Trial Research group. Impact of incident diabetes and incident nonfatal cardiovascular disease on 18‐year mortality: the multiple risk factor intervention trial experience. Diabetes Care 2003; 26: 848–854. CT
  • Verdecchia P., Reboldi G., Angeli F., Borgioni C., Gattobigio R., Filippucci L., Norgiolini S., Bracco C., Porcellati C. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963–969. OS
  • Almgren T., Willemsen O., Samuelsson O., Himmelmann A., Rosengren A., Anderson O. K. Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from 20 years follow up. J Hypertens 2007, in press. OS
  • Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and the risk of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272–298. MA
  • Sever P. S., Poulter N. R., Dahlof B., Wedel H., Anglo‐Scandinavian Cardiac Outcomes Trial Investigators. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo‐Scandinavian Cardiac Outcomes Trial‐Lipid‐Lowering Arm (ASCOT‐LLA). Am J Cardiol 2005; 96: 39F–44F. RT
  • Atkins R. C., Briganti E. M., Lewis J. B., Hunsicker L. G., Braden G., Champion de Crespigny P. J., DeFerrari G., Drury P., Locatelli F., Wiegmann T. B., Lewis E. J. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281–287. OS
  • The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin‐converting enzyme inhibitors? A meta‐analysis of individual patient data. Ann Int Med 2001; 134: 370–379. MA
  • Parving H. H., Hommel E., Jensen B. R., Hansen H. P. Long‐term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001; 60: 228–234. OS
  • Julius S., Nesbitt S. D., Egan B. M., Weber M. A., Michelson E. L., Kaciroti N., Black H. R., Grimm R. H., Jr., Messerli F. H., Oparil S., Schork M. A., Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin‐receptor blocker. N Engl J Med 2006; 354: 1685–1697. RT
  • Weber M. A., Julius S., Kjeldsen S. E., Brunner H. R., Ekman S., Hansson L., Hua T., Laragh J. H., McInnes G. T., Mitchell L., Plat F., Schork M. A., Smith B., Zanchetti A. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051. CT
  • Pepine C. J., Kowey P. R., Kupfer S., Kolloch R. E., Benetos A., Mancia G., Coca A., Cooper‐DeHoff R. M., Handberg E., Gaxiola E., Sleight P., Conti C. R., Hewkin A. C., Tavazzi L., INVEST Investigators. Predictors of adverse outcome among patients with hypertension and coronary artery disease. J Am Coll Cardiol 2006; 47: 547–551. OS
  • Benetos A., Thomas F., Bean K. E., Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens 2003; 21: 1635–1640. OS
  • Arima H., Chalmers J., Woodward M., Anderson C., Rodgers A., Davis S., Macmahon S., Neal B., PROGRESS Collaborative Group. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006; 24: 1201–1208. OS
  • Zanchetti A., Hansson L., Clement D., Elmfeldt D., Julius S., Rosenthal T., Waeber B., Wedel H., HOT Study Group. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles: does a J‐shaped curve exist in smokers?. J Hypertens 2003; 21: 797–804. CT
  • Freemantle N., Cleland J., Young P., Mason J., Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. Br Med Journal 1999; 318: 1730–1737. MA
  • Shekelle P. G., Rich M. W., Morton S. C., Atkinson C. S., Tu W., Maglione M., Rhodes S., Barrett M., Fonarow G. C., Greenberg B., Heidenreich P. A., Knabel T., Konstam M. A., Steimle A., Warner Stevenson L. Efficacy of angiotensin‐converting enzyme inhibitors and beta‐blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta‐analysis of major clinical trials. JAm Coll Cardiol 2003; 41: 1529–1538. MA
  • Sega R., Cesana G., Milesi C., Grassi G., Zanchetti A., Mancia G. Ambulatory and home blood pressure normality in the elderly: data from the PAMELA population. Hypertension 1997; 30: 1–6. OS
  • Mancia G., Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta‐analysis. J Hypertens 2004; 22: 435–445. MA
  • Messerli F. H., Mancia G., Conti C. R., Hewkin A. C., Kupfer S., Champion A., Kolloch R., Benetos A., Pepine C. J. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?. Ann Intern Med 2006; 144: 884–893. OS
  • Boutitie F., Gueyffier F., Pocock S., Fagard R., Boissel J. P., INDANA Project Steering Committee. INdividual Data ANalysis of Antihypertensive intervention. J‐shaped relationship between blood pressure and mortality in hypertensive patients: new insights from a meta‐analysis of individual‐patient data. Ann Intern Med 2002; 136: 438–448. MA
  • Samuelsson O. G., Wilhelmsen L. W., Pennert K. M., Wedel H., Berglund G. L. The J‐shaped relationship between coronary heart disease and achieved blood pressure level in treated hypertension: further analyses of 12 years of follow‐up of treated hypertensives in the Primary Prevention Trial in Gothenburg, Sweden. J Hypertens 1990; 8: 547–555. OS
  • Cruickshank J. M., Pennert K., Sorman A. E., Thorp J. M., Zacharias F. M., Zacharias F. J. Low mortality from all causes, including myocardial infarction, in well‐controlled hypertensives treated with a beta‐blocker plus other antihypertensives. J Hypertens 1987; 5: 489–498. OS
  • Staessen J., Bulpitt C., Clement D., De Leeuw P., Fagard R., Fletcher A., Forette F., Leonetti G., Nissinen A., O'Malley K. Relation between mortality and treated blood pressure in elderly patients with hypertension: report of the European Working Party on High Blood Pressure in the Elderly. Br Med J 1989; 298: 1552–1556. CT
  • Bonet S., Agusti A., Arnau J. M., Vidal X., Diogene E., Galve E., Laporte J. R. Beta‐adrenergic blocking agents in heart failure: benefits of vasodilating and non‐vasodilating agents according to patients' characteristics: a metaanalysis of clinical trials. Arch Intern Med 2000; 160: 621–627. MA
  • Mancia G., Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 2002; 20: 1461–1464. RV
  • Mancia G., Brown M., Castaigne A., de Leeuw P., Palmer C. R., Rosenthal T., Wagener G., Ruilope L. M., INSIGHT. Outcomes with nifedipine GITS or Co‐amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431–436. RT
  • Ambrosioni E. Pharmacoeconomic challenges in disease management of hypertension. J Hypertens 2001; 19((Suppl 3))S33–S40. RV
  • Schulzer M., Mancini G. B. ‘Unqualified success’ and ‘unmitigated failure’: number‐needed‐to‐treat‐related concepts for assessing treatment efficacy in the presence of treatment‐induced adverse events. Int J Epidemiol 1996; 25: 704–712. RV
  • Zanchetti A., Mancia G. Benefits and cost‐effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. J Hypertens 1996; 14: 809–811. RV
  • Zanchetti A., Hansson L., Menard J., Leonetti G., Rahn K. H., Warnold I., Wedel H. Risk assessment and treatment benefit in intensively treated hypertensive patients of the Hypertension Optimal Treatment (HOT) study. J Hypertens 2001; 19: 819–825. OS
  • Zanchetti A. Costs of implementing recommendations on hypertension management given in recent guidelines. J Hypertens 2003; 21: 2207–2209. RV
  • Moser M. Are lifestyle interventions in the management of hypertension effective? How long should you wait before starting specific medical therapy? An ongoing debate. J Clin Hypertens 2005; 7: 324–326. RV
  • Dickinson H. O., Mason J. M., Nicolson D. J., Campbell F., Beyer F. R., Cook S. W., Williams B., Ford G. A. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomised controlled trials. J Hypertens 2006; 24: 215–233. MA
  • Haynes R. B., McDonald H. P., Garg A. X. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288: 2880–2883
  • Groppelli A., Giorgi D. M., Omboni S., Parati G., Mancia G. Persistent blood pressure increase induced by heavy smoking. J Hypertens 1992; 10: 495–499
  • Grassi G., Seravalle G., Calhoun D. A., Bolla G. B., Giannattasio C., Marabini M., Del Bo A., Mancia G. Mechanisms responsible for sympathetic activation by cigarette smoking in humans. Circulation 1994; 90: 248–253
  • Narkiewicz K., van de Borne P. J., Hausberg M., Cooley R. L., Winniford M. D., Davison D. E., Somers V. K. Cigarette smoking increases sympathetic outflow in humans. Circulation 1998; 98: 528–534
  • Seltzer C. C. Effect of smoking on blood pressure. Am Heart J 1974; 87: 558–564
  • Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Zampi I., Battistelli M., Gattobigio R., Sacchi N., Porcellati C. Cigarette smoking, ambulatory blood pressure and cardiac hypertrophy in essential hypertension. J Hypertens 1995; 13: 1209–1215. OS
  • Mann S. J., James G. D., Wang R. S., Pickering T. G. Elevation of ambulatory systolic blood pressure in hypertensive smokers. A case‐control study. JAMA 1991; 265: 2226–2228. OS
  • Bang L. E., Buttenschon L., Kristensen K. S., Svendsen T. L. Do we undertreat hypertensive smokers? A comparison between smoking and non‐smoking hypertensives. Blood Press Monit 2000; 5: 271–274
  • Mundal R., Kjeldsen S. E., Sandvik L., Erikssen G., Thaulow E., Erikssen J. Predictors of 7‐year changes in exercise blood pressure: effects of smoking physical fitness pulmonary function. J Hypertens 1997; 15: 245–249. OS
  • Primatesta P., Falaschetti E., Gupta S., Marmot M. G., Poulter N. R. Association between smoking and blood pressure: evidence from the health survey for England. Hypertension 2001; 37: 187–193. OS
  • Omvik P. How smoking affects blood pressure. Blood Press 1996; 5: 71–77. RV
  • Doll R., Peto R., Wheatley K., Gray R., Sutherland I. Mortality in relation to smoking: 40 years' observations on male British doctors. Br Med J 1994; 309: 901–911. OS
  • Rosenberg L., Kaufman D. W., Helmrich S. P., Shapiro S. The risk of myocardial infarction after quitting smoking in men under 55 years of age. N Engl J Med 1985; 313: 1511–1514. OS
  • Manson J. E., Tosteson H., Ridker P. M., Satterfield S., Hebert P., O'Connor G. T., Buring J. E., Hennekens C. H. The primary prevention of myocardial infarction. N Engl J Med 1992; 326: 1406–1416
  • Wilson K., Gibson N., Willan A., Cook D. Effect of smoking cessation on mortality after myocardial infarction: meta‐analysis of cohort studies. Arch Intern Med 2000; 160: 939–944. MA
  • Tsevat J., Weinstein M. C., Williams L. W., Tosteson A. N., Goldman L. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991; 83: 1194–1201. OS
  • Silagy C., Mant D., Fowler G., Lodge M. Meta‐analysis on efficacy of nicotine replacement therapies in smoking cessation. Lancet 1994; 343: 139–142. MA
  • Tonstad S., Farsang C., Klaene G., Lewis K., Manolis A., Perruchoud A. P., Silagy C., van Spiegel P. I., Astbury C., Hider A., Sweet R. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J 2003; 24: 946–955. RT
  • Nides M., Oncken C., Gonzales D., Rennard S., Watsky E. J., Anziano R., Reeves K. R. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7‐week, randomized, placebo‐ and bupropion‐controlled trial with 1‐year follow‐up. Arch Intern Med 2006; 166: 1561–1568. RT
  • Law M. R., Morris J. K., Wald N. J. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. Br Med J 1997; 315: 973–980. RV
  • Stranges S., Bonner M. R., Fucci F., Cummings K. M., Freudenheim J. L., Dorn J. M., Muti P., Giovino G. A., Hyland A., Trevisan M. Lifetime cumulative exposure to secondhand smoke and risk of myocardial infarction in never smokers: results from the Western New York health study, 1995–2001. Arch Intern Med 2006; 166: 1961–1967. OS
  • Rimm E. B., Williams P., Fosher K., Criqui M., Stampfer M. J. Moderate alcohol intake and lower risk of coronary heart disease: meta‐analysis of effects on lipids and haemostatic factors. Br Med J 1999; 319: 1523–1528. MA
  • Fillmore K. M., Kerr W. C., Stockwell T., Chikritzhs T., Bostrom A. Moderate alcohol use and reduced mortality risk: Systematic error in prospective studies. Addiction Research & Theory 2006; 14: 101–132. RV
  • Puddey I. B., Beilin L. J., Rakie V. Alcohol, hypertension and the cardiovascular system: a critical appraisal. Addiction Biol 1997; 2: 159–170. RV
  • Wannamethee S. G., Shaper A. G. Patterns of alcohol intake and risk of stroke in middle‐aged British men. Stroke 1996; 27: 1033–1039. OS
  • Puddey I. B., Beilin L. J., Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. A randomised controlled trial. Lancet 1987; 1: 647–651. RT
  • Law M. R. Epidemiologic evidence on salt and blood pressure. Am J Hypertens 1997; 10((Suppl 5))S42–S45. RV
  • Joint WHO/FAO Expert report on diet, nutrition, the prevention of chronic disease. Executive Summary. www.who.int. RV
  • Cutler J. A., Follman D., Alexander P. S. Randomized controlled trials of sodium reduction: an overview. Am J Clin Nutr 1997; 65((Suppl 2))S643–S651. MA
  • Graudal N. A., Galloe A. M., Garred P. Effects of sodium restriction on blood pressure, renin, aldosterone, catecholamines, cholesterols, and triglyceride: a meta‐analysis. JAMA 1998; 279: 1383–1391. MA
  • He F. J., MacGregor G. A. How far should salt intake be reduced?. Hypertension 2003; 42: 1093–1099. RV
  • Robertson J. I. J. Dietary salt and hypertension: a scientific issue or a matter of faith?. J Eval Clin Pract 2003; 9: 1–22. RV
  • Australian National Health Medical Research Council Dietary Salt Study Management Committee. Effects of replacing sodium intake in subjects on a low sodium diet a crossover study. Clin Exp Hypertens 1989; A11: 1011–1024
  • He F. J., Markandu N. D., MacGregor G. A. Importance of the renin system for determining blood pressure fall with acute salt restriction in hypertensive and normotensive whites. Hypertension 2001; 38: 321–325. OS
  • Grassi G., Dell'Oro R., Seravalle G., Foglia G., Quarti Trevano F., Mancia G. Short‐ and long‐term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension. Circulation 2002; 106: 1957–1961
  • Grassi G., Cattaneo B. M., Seravalle G., Lanfranchi A., Bolla G., Mancia G. Baroreflex impairment by low sodium diet in mild or moderate essential hypertension. Hypertension 1997; 29: 802–807
  • Appel L. J., Brands M. W., Daniels S. R., Karanja N., Elmer P. J., Sacks F. M., American Heart Association. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension 2006; 47: 296–308. GL
  • Otten J., Pitzi Helliwig J., Meyers L. D. The dietary reference intakes: the essential guide to nutrient requirements. National Academies Press, Washington, DC 2006, RV
  • Sacks F. M., Svetkey L. P., Vollmer W. M., Appel L. J., Bray G. A., Harsha D., Obarzanek E., Conlin P. R., Miller E. R., 3rd., Simons‐Morton D. G., Karanja N., Lin P. H., DASH‐Sodium Collaborative Research Group. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH‐Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3–10. RT
  • Morris M. C., Sacks F., Rosner B. Does fish oil lower blood pressure? A meta‐analysis of controlled trials. Circulation 1993; 88: 523–533. MA
  • Geleijnse J. M., Giltay E. J., Grobbee D. E., Donders A. R., Kok F. J. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 2002; 20: 1493–1499. MA
  • Appel L. J., Miller E. R., 3rd., Seidler A. J., Whelton P. K. Does supplementation of diet with ‘fish oil’ reduce blood pressure? A meta‐analysis of controlled clinical trials. Arch Intern Med 1993; 153: 1429–1438. MA
  • He J., Whelton P. K. Effect of dietary fiber and protein intake on blood pressure: a review of epidemiologic evidence. Clin Exp Hypertens 1999; 21: 785–796. RV
  • He J., Streiffer R. H., Muntner P., Krousel‐Wood M. A., Whelton P. K. Effect of dietary fiber intake on blood pressure: a randomized, double‐blind, placebo‐controlled trial. J Hypertens 2004; 22: 73–80. RT
  • Griffith L. E., Guyatt G. H., Cook R. J., Bucher H. C., Cook D. J. The influence of dietary and nondietary calcium supplementation on blood pressure: an updated metaanalysis of randomized controlled trials. Am J Hypertens 1999; 12: 84–92. MA
  • Jee S. H., Miller E. R., 3rd., Guallar E., Singh V. K., Appel L. J., Klag M. J. The effect of magnesium supplementation on blood pressure: a meta‐analysis of randomized clinical trials. Am J Hypertens 2002; 15: 691–696. MA
  • Visvanathan R., Chen R., Horowitz M., Chapman I. Blood pressure responses in healthy older people to 50 g carbohydrate drinks with differing glycaemic effects. Br J Nutr 2004; 92: 335–340. OS
  • Pereira M. A., Swain J., Goldfine A. B., Rifai N., Ludwig D. S. Effects of a low‐glycemic load diet on resting energy expenditure and heart disease risk factors during weight loss. JAMA 2004; 292: 2482–2490. OS
  • Margetts B. M., Beilin L. J., Vandongen R., Armstrong B. K. Vegetarian diet in mild hypertension: a randomised controlled trial. Br Med J 1986; 293: 1468–1471. RT
  • Bao D. Q., Mori T. A., Burke V., Puddey I. B., Beilin L. J. Effects of dietary fish and weight reduction on ambulatory blood pressure in overweight hypertensives. Hypertension 1998; 32: 710–717. OS
  • Daniels S. R., Kimball T. R., Khoury P., Witt S., Morrison J. A. Correlates of the hemodynamic determinants of blood pressure. Hypertension 1996; 28: 37–41. OS
  • Stamler J. Epidemiologic findings on body mass and blood pressure in adults. Ann Epidemiol 1991; 1: 347–362. OS
  • Neter J. E., Stam B. E., Kok F. J., Grobbee D. E., Geleijnse J. M. Influence of weight reduction on blood pressure: a meta‐analysis of randomized controlled trials. Hypertension 2003; 42: 878–884. MA
  • Stevens V. J., Corrigan S. A., Obarzanek E., Bernauer E., Cook N. R., Hebert P., Mattfeldt‐Beman M., Oberman A., Sugars C., Dalcin A. T. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993; 153: 849–858. CT
  • Stevens V. J., Obarzanek E., Cook N. R., Lee I. M., Appel L. J., Smith West D., Milas N. C., Mattfeldt‐Beman M., Belden L., Bragg C., Millstone M., Raczynski J., Brewer A., Singh B., Cohen J., Trials for the Hypertension Prevention Research Group. Long‐term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med 2001; 134: 1–11. RT
  • Huang Z., Willett W. C., Manson J. E., Rosner B., Stampfer M. J., Speizer F. E., Colditz G. A. Body weight, weight change, and risk for hypertension in women. Ann Intern Med 1998; 128: 81–88. OS
  • The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high‐normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157: 657–667. RT
  • Langford H. G., Blaufox M. D., Oberman A., Hawkins C. M., Curb J. D., Cutter G. R., Wassertheil‐Smoller S., Pressel S., Babcock C., Abernethy J. D. Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 1985; 253: 657–664. RT
  • Whelton P. K., Appel L. J., Espeland M. A., Applegate W. B., Ettinger W. H., Jr., Kostis J. B., Kumanyika S., Lacy C. R., Johnson K. C., Folmar S., Cutler J. A. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279: 839–846. RT
  • Sandvik L., Erikssen J., Thaulow E., Erikssen G., Mundal R., Rodahl K. Physical fitness as a predictor of mortality among healthy, middle‐aged Norwegian men. N Engl J Med 1993; 328: 533–537. OS
  • Cornelissen V. A., Fagard R. H. Effects of endurance training on blood pressure, blood pressure‐regulating mechanisms, and cardiovascular risk factors. Hypertension 2005; 46: 667–675. OS
  • Fagard R. H. Exercise characteristics and the blood pressure response to dynamic physical training. Med Sci Sports Exerc 2001; 33: S484–S492. OS
  • Cornelissen V. A., Fagard R. H. Effect of resistance training on resting blood pressure: a meta‐analysis of randomized controlled trials. J Hypertens 2005; 23: 251–259. MA
  • Jennings G. L. Exercise, blood pressure: Walk, run or swim?. J Hypertens 1997; 15: 567–569. RV
  • Stringer W. W., Wasserman K. Statement on exercise: American College of Chest Physicians/American Thoracic Society‐exercise for fun or profit?. Chest 2005; 127: 1072–1073. GL
  • Fagard R. H., Bjornstad H. H., Borjesson M., Carre F., Deligiannis A., Vanhees L., European Society of Cardiology. ESC Study Group of Sports Cardiology recommendations for participation in leisure‐time physical activities and competitive sports for patients with hypertension. Eur J Cardiovasc PrevRehabil 2005; 12: 326–331. GL
  • Heidenreich P. A., McDonald K. M., Hastie T., Fadel B., Hagan V., Lee B. K., Hlatky M. A. Meta‐analysis of trials comparing beta‐blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999; 281: 1927–1936. MA
  • Sharma A. M., Pischon T., Hardt S., Kunz I., Luft F. C. Hypothesis: Beta‐adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001; 37: 250–254. RV
  • Lindholm L. H., Ibsen H., Borch‐Johnsen K., Olsen M. H., Wachtell K., Dahlof B., Devereux R. B., Beevers G., de Faire U., Fyhrquist F., Julius S., Kjeldsen S. E., Kristianson K., Lederballe‐Pedersen O., Nieminen M. S., Omvik P., Oparil S., Wedel H., Aurup P., Edelman J. M., Snapinn S., For the LIFE study group. Risk of new‐onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879–1886. RT
  • Kjeldsen S. E., Julius S., Mancia G., McInnes G. T., Hua T., Weber M. A., Coca A., Ekman S., Girerd X., Jamerson K., Larochelle P., MacDonald T. M., Schmieder R. E., Schork M. A., Stolt P., Viskoper R., Widimsky J., Zanchetti A., VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high‐risk hypertensive patients: the VALUE trial. J Hypertens 2006; 24: 1405–1412. RT
  • Torp‐Pedersen C., Metra M., Charlesworth A., Spark P., Lukas M. A., Poole‐Wilson P. A., Swedberg K., Cleland J. G., Di Lenarda A., Remme W., Scherhaug A. Effects of metoprolol and carvedilol on preexisting and new onset diabetes in patients with chronic heartfailure Data from the Carvedilol or metoprolol European Trial (COMET). Heart 2007, in press. RT
  • Kaiser T., Heise T., Nosek L., Eckers U., Sawicki P. T. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006; 24: 1397–1403. RT
  • Cushman W. C., Reda D. J., Perry H. M., Williams D., Abdellatif M., Materson B. J. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 2000; 160: 825–831. CT
  • Van Zwieten P. A. Centrally acting antihypertensive drugs. Manual of Hypertension, G Mancia, J Chalmers, S Julius, T Saruta, M Weber. Churchill Livingston, London 2002; 401–410. RV
  • Zannad F. Aldosterone antagonist therapy in resistant hypertension. J Hypertens 2007; 25: 747–750. RV
  • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid‐Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–1975. RT
  • Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69: 1503–1506. RV
  • Villamil A., Chrysant S. G., Calhoun D., Schober B., Hsu H., Matrisciano‐Dimichino L., Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217–226. RT
  • O'Brien E., Barton J., Nussberger J., Mulcahy D., Jensen C., Dicker P., Stanton A. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin‐converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276–284. RT
  • Gradman A. H., Schmieder R. E., Lins R. L., Nussberger J., Chiang Y., Bedigian M. P. Aliskiren, a novel orally effective renin inhibitor, provides dose‐dependent antihypertensive efficacy and placebo‐like tolerability in hypertensive patients. Circulation 2005; 111: 1012–1018. RT
  • Pilz B., Shagdarsuren E., Wellner M., Fiebeler A., Dechend R., Gratze P., Meiners S., Feldman D. L., Webb R. L., Garrelds I. M., Jan Danser A. H., Luft F. C., Muller D. N. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double‐transgenic rats. Hypertension 2005; 46: 569–576
  • Alderman M. H., Madhavan S., Ooi W. L., Cohen H., Sealey J. E., Laragh J. H. Association of the renin‐sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098–1104. OS
  • Ruilope L. M., Agabiti‐Rosei E., Bakris G. L., Mancia G., Poulter N. R., Taddei S., Unger T., Volpe M., Waeber B., Zannad F. Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press 2005; 14: 196–209. RV
  • Waeber B., Burnier M., Brunner H. R. Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21: 973–985. RV
  • Parati G., Omboni S., Rizzoni D., Agabiti‐Rosei E., Mancia G. The smoothness index: a new, reproducible and clinically relevant measure of the homogeneity of the blood pressure reduction with treatment for hypertension. J Hypertens 1998; 16: 1685–1691
  • Ambrosioni E., Leonetti G., Pessina A. C., Rappelli A., Trimarco B., Zanchetti A. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive Therapy. J Hypertens 2000; 18: 1691–1699. OS
  • Law M. R., Wald N. J., Morris J. K., Jordan R. E. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003; 326: 1427. MA
  • Materson B. J., Reda D. J., Cushman W. C. Department of Veterans Affairs single‐drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995; 8: 189–192. RT
  • Morgan T. O., Anderson A. I., MacInnis R. J. ACE inhibitors, beta‐blockers, calcium blockers, and diuretics for the control of systolic hypertension. Am J Hypertens 2001; 14: 241–247. RV
  • Dickerson J. E., Hingorani A. D., Ashby M. J., Palmer C. R., Brown M. J. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008–2013. OS
  • Hoes A. W., Grobbee D. E., Lubsen J., Man in 't Veld A. J., van der Does E., Hofman A. Diuretics, beta‐blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995; 123: 481–487. OS
  • Helderman J. H., Elahi D., Andersen D. K., Raizes G. S., Tobin J. D., Shocken D., Andres R. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32: 106–111. OS
  • Conn J. W. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med 1965; 273: 1135–1143. RV
  • Ferrari P., Marti H. P., Pfister M., Frey F. J. Additive antiproteinuric effect of combined ACE, inhibition and angiotensin II receptor blockade. J Hypertens 2002; 20: 125–130. RT
  • McMurray J. J., Ostergren J., Swedberg K., Granger C. B., Held P., Michelson E. L., Olofsson B., Yusuf S., Pfeffer M. A., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left‐ventricular systolic function taking angiotensin‐converting‐enzyme inhibitors: the CHARM‐Added trial. Lancet 2003; 362: 767–771. RT
  • Giannattasio C., Achilli F., Failla M., Capra A., Vincenzi A., Valagussa F., Mancia G. Radial, carotid, aortic distensibility in congestive heart failure: effects of high‐dose angiotensin‐converting enzyme inhibitor or low‐dose association with angiotensin type 1 receptor blockade. JAm Coll Cardiol 2002; 39: 1275–1282. OS
  • Bangalore S., Kamalakkannan G., Panjrath G., Messerli F. H. Fixed‐dose combination improves medication compliance: a meta‐analysis. J Clin Hypertens 2006; 8((Suppl A))A72 (abstract). MA
  • Jamerson K. A., Bakris G. L., Wun C. C., Dahlof B., Lefkowitz M., Manfreda S., Pitt B., Velazquez E. J., Weber M. A. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first‐line combination therapies in hypertension. Am J Hypertens 2004; 17: 793–801. RT
  • Gueyffier F., Bulpitt C., Boissel J. P., Schron E., Ekbom T., Fagard R., Casiglia E., Kerlikowske K., Coope J. Antihypertensive drugs in very old people: a subgroup analysis of randomised controlled trials. Lancet 1999; 353: 793–796. MA
  • Bulpitt C. J., Beckett N. S., Cooke J., Dumitrascu D. L., Gil‐Extremera B., Nachev C., Nunes M., Peters R., Staessen J. A., Thijs L., Hypertension in the Very Elderly Trial Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–2417. RT
  • Messerli F. H., Grossman E., Goldbourt U. Are beta‐blockers efficacious as first‐line therapy for hypertension in the elderly?. JAMA 1998; 279: 1903–1907. MA
  • Kjeldsen S. E., Dahlof B., Devereux R. B., Julius S., Aurup P., Edelman J., Beevers G., de Faire U., Fyhrquist F., Ibsen H., Kristianson K., Lederballe‐Pedersen O., Lindholm L. H., Nieminen M. S., Omvik P., Oparil S., Snapinn S., Wedel H., LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288: 1491–1498. CT
  • Papademetriou V., Farsang C., Elmfeldt D., Hofman A., Lithell H., Olofsson B., Skoog I., Trenkwalder P., Zanchetti A., Study on Cognition, Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1‐receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175–1180. CT
  • Lakatta E. G. Deficient neuroendocrine regulation of the cardiovascular system with advancing age in healthy humans. Circulation 1993; 87: 631–636. RV
  • Fagard R. H., Van den Enden M., Leeman M., Warling X. Survey on treatment of hypertension and implementation of WHO‐ISH risk stratification in primary care in Belgium. J Hypertens 2002; 20: 1297–1302. OS
  • Somes G. W., Pahor M., Shorr R. I., Cushman W. C., Applegate W. B. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159: 2004–2009. OS
  • Fagard R. H., Staessen J. A., Thijs L., Celis H., Bulpitt C. J., de Leeuw P. W., et al. On‐treatment diastolic blood pressure and prognosis in systolic Hypertension. Arch Intern Med 2007, in press. OS
  • Mogensen C. E. Long‐term antihypertensive treatment inhibiting progression of diabetic nephropathy. Br Med J 1982; 285: 685–688. OS
  • Mancia G. The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction. Acta Diabetol 2005; 42((Suppl 1))S17–S25. RV
  • Colhoun H. M., Betteridge D. J., Durrington P. N., Hitman G. A., Neil H. A., Livingstone S. J., Thomason M. J., Mackness M. I., Charlton‐Menys V., Fuller J. H., CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo‐controlled trial. Lancet 2004; 364: 685–696. RT
  • Bosch J., Yusuf S., Pogue J., Sleight P., Lonn E., Rangoonwala B., Davies R., Ostergren J., Probstfield J., HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. Br Med J 2002; 324: 699–701. RT
  • Trenkwalder P., Elmfeldt D., Hofman A., Lithell H., Olofsson B., Papademetriou V., Skoog I., Zanchetti A., The Study on Cognition. Prognosis in the Elderly (SCOPE). The Study on Cognition and Prognosis in the Elderly (SCOPE) ‐ major cardiovascular events and stroke in subgroups of patients. Blood Press 2005; 14: 31–37. CT
  • Bathl P., Chalmersl J., Powersl W., Beilinl L., Davisl S., Lenfantl C., Mancial G., Neall B., Whitworthl J., Zanchettil A., International Society of Hypertension Writing Group. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J Hypertens 2003; 21: 665–672. GL
  • Schrader J., Luders S., Kulschewski A., Berger J., Zidek W., Treib J., Einhaupl K., Diener H. C., Dominiak P., Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–1703. RT
  • COSSACS Trial Group. COSSACS (Continue or Stop post‐Stroke Antihypertensives Collaborative Study): rationale and design. J Hypertens 2005; 23: 455–458. RT
  • Potter J., Robinson T., Ford G., James M., Jenkins D., Mistri A., Bulpitt C., Drummond A., Jagger C., Knight J., Markus H., Beevers G., Dewey M., Lees K., Moore A., Paul S., The CHHIPS Trial Group. CHHIPS (Controlling Hypertension and Hypotension Immediately Post‐Stroke) Pilot Trial: rationale and design. J Hypertens 2005; 23: 649–655. RT
  • van Dijk E. J., Breteler M. M., Schmidt R., Berger K., Nilsson L. G., Oudkerk M., Pajak A., Sans S., de Ridder M., Dufouil C., Fuhrer R., Giampaoli S., Launer L. J., Hofman A., CASCADE Consortium. The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004; 44: 625–630. OS
  • Vermeer S. E., Hollander M., van Dijk E. J., Hofman A., Koudstaal P. J., Breteler M. M., Rotterdam Scan Study. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke 2003; 34: 1126–1129. OS
  • Vermeer S. E., Prins N. D., den Heijer T., Hofman A., Koudstaal P. J., Breteler M. M. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348: 1215–1222. OS
  • Sierra C., de La Sierra A., Mercader J., Gomez‐Angelats E., Urbano‐Marquez A., Coca A. Silent cerebral white matter lesions in middle‐aged essential hypertensive patients. J Hypertens 2002; 20: 519–524. OS
  • Qiu C., Winblad B., Fratiglioni L. The age‐dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487–499. RV
  • Kannel W. B. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13((Suppl 1))S3–S10. RV
  • Yap Y. G., Duong T., Bland J. M., Malik M., Torp‐Pederson C., Kober L., Connolly S. J., Gallagher M. M., Camm A. J. Prognostic value of blood pressure measured during hospitalization after acute myocardial infarction: an insight from survival trials. J Hypertens 2007; 25: 307–313. OS
  • Domanski M. J., Mitchell G. F., Norman J. E., Exner D. V., Pitt B., Pfeffer M. A. Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33: 951–958. OS
  • Lee V. C., Rhew D. C., Dylan M., Badamgarav E., Braunstein G. D., Weingarten S. R. Meta‐analysis: angiotensin‐receptor blockers in chronic heart failure and high‐risk acute myocardial infarction. Ann Intern Med 2004; 141: 693–704. MA
  • Yusuf S., Pfeffer M. A., Swedberg K., Granger C. B., Held P., McMurray J. J., Michelson E. L., Olofsson B., Ostergren J., CHARM Investigators Committees. Effects of candesartan in patients with chronic heart failure and preserved left‐ventricular ejection fraction: the CHARM‐Preserved Trial. Lancet 2003; 362: 777–781
  • Kannel W. B., Wolf P. A., Benjamin E. J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population‐based estimates. Am J Cardiol 1998; 82: 2N–9N. OS
  • Hankey G. J. Preventable stroke and stroke prevention. J Thromb Haemost 2005; 3: 1638–1645. RV
  • Lip G. Y., Frison L., Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007; 28: 752–759. OS
  • Healey J. S., Baranchuk A., Crystal E., Morillo C. A., Garfinkle M., Yusuf S., Connolly S. J. Prevention of atrial fibrillation with angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers: a meta‐analysis. J Am Coll Cardiol 2005; 45: 1832–1839. MA
  • Perera G. A. Hypertensive vascular disease: description and natural history. J Chronic Dis 1955; 1: 33–42
  • Redon J., Rovira E., Miralles A., Julve R., Pascual J. M. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39: 794–798. OS
  • Lawes C. M. M., Vander Hoorn S., Law M. R., Elliott P., MacMahon S., Rodgers A. Blood pressure and the global burden of disease 2000. Part I: Estimates of blood pressure levels. J Hypertens 2006; 24: 413–422. OS
  • Franklin S. S., Gustin W 4th., Wong N. D., Larson M. G., Weber M. A., Kannel W. B., Levy D. Hemodynamic patterns of age‐related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308–315. OS
  • Wilson P. W., Castelli W. P., Kannel W. B. Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol 1987; 59: 91G–94G. RV
  • Zanchetti A., Julius S., Kjeldsen S., McInnes G. T., Hua T., Weber M., Laragh J. H., Plat F., Battegay E., Calvo‐Vargas C., Cieslinski A., Degaute J. P., Holwerda N. J., Kobalava J., Pedersen O. L., Rudyatmoko F. P., Siamopoulos K. C., Storset O. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163–2168. CT
  • Dong W., Colhoun H. M., Poulter N. R. Blood pressure in women using oral contraceptives results from the Health Survey for England 1994. J Hypertens 1997; 15: 1063–1068. OS
  • Chasan‐Taber L., Willett W. C., Manson J. A. E., Spiegelman D., Hunter D. J., Curhan G., Colditz G. A., Stampfer M. J. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483–489. OS
  • Lip G. Y., Beevers M., Beevers D. G. Malignant hypertension in young women is related to previous hypertension in pregnancy, not oral contraception. Quart J Med 1997; 90: 571–575. OS
  • Woods J. W. Oral contraceptives and hypertension. Hypertension 1998; 11: II11–II15. RV
  • Kawano H., Motoyama T., Kugiyama K., Hirashima O., Ohgushi M., Fujii H., Ogawa H., Yasue H. Gender difference in improvement of endothelium‐dependent vasodilation after estrogen supplementation. J Am Coll Cardiol 1997; 30: 914–919. OS
  • Skinner S. L., Lumbers E. R., Symonds E. M. Alteration by oral contraceptives of normal menstrual changes in plasma renin activity, concentration and substrate. Clin Sci 1969; 36: 67–76. OS
  • Giannattasio C., Failla M., Grappiolo A., Stella M. L., Del Bo A., Colombo M., Mancia G. Fluctuations of radial artery distensibility throughout the menstrual cycle. Arterioscler Thromb Vasc Biol 1999; 19: 1925–1929
  • Ribstein J., Halimi J‐M., Guilhem du Cailar, Mimran A. Renal characteristics and effect of angiotensin suppression in oral contraceptive users. Hypertension 1999; 33: 90–95
  • Inman W. H. W., Vessey M. P. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of childbearing age. BMJ 1968; 2: 193–199. OS
  • Vessey M. P., Doll R. Investigation of the relation between use of oral contraceptives and thromboembolic disease. BMJ 1968; 2: 199–205. OS
  • Masi A. T., Dudgate M. Cerebrovascular disease associated with the use of oral contraceptives: a review of the English‐language literature. Ann Intern Med 1970; 72: 111–121. RV
  • Han W‐S., Ray J., Wai E. K., Ginsburg S., Hannah M. E., Corey P. N., Ginsberg J. S. Risk of stroke in women exposed to low‐dose oral contraceptives. A critical evaluation of the evidence. Arch Intern Med 2004; 164: 741–747. MA
  • Curtis K. M., Mohllajee A. P., Martins S. L., Peterson H. B. Combined oral contraceptive use among women with hypertension: a systematic review. Contraception 2006; 73: 179–188. MA
  • Gomes M. P., Deitcher S. R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. Arch Intern Med 2004; 164: 1965–1976. OS
  • Hussain S. F. Progestogen‐only pills and high blood pressure: is there an association? A literature review. Contraception 2004; 69: 89–97. RV
  • Zanchetti A., Facchetti R., Cesana G. C., Modena G. M., Pirrelli A., Sega R. Menopause‐related blood pressure increase and its relationship to age and body mass index: the SIMONA epidemiological study. J Hypertens 2005; 23: 2269–2276. OS
  • Shelley J. M., Green A., Smith A. M., Dudley E., Dennerstein L., Hopper J., Burger H. Relationship of sex hormones to lipids and blood pressure in mid‐aged women. Ann Epidemiol 1998; 8: 39–45. OS
  • Grobbee D. E., Van Hemert A. M., Vanderbroucke J. P., Hofman A., Valkenburg H. A. Importance of body weight in determining risk and level of blood pressure in postmenopausal women. J Hypertens 1988; 6((Suppl))S614–S616. OS
  • Staessen J. A., Ginocchio G., Thijs L., Fagard R. Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens 1997; 11: 507–514. OS
  • Casiglia E., d'Este D., Ginocchio G., Colangeli G., Onesto C., Tramontin P., Ambrosio G. B., Pessina A. C. Lack of influence of menopause on blood pressure and cardiovascular risk profile: a 16 year longitudinal study concerning a cohort of 568 women. J Hypertens 1996; 14: 729–736. OS
  • Lindqvist O., Bengtsson C. Serum lipids arterial blood pressure body weight in relation to the menopause: results from a population study of women in Goteborg Sweden. Scand J Clin Invest 1980; 40: 629–636. OS
  • Torng P. L., Su T. C., Sung F. G., Chien K. L., Huang S. C., Chon S. N., Lee Y. T. Effects of menopause on intraindividual changes in serum lipids, blood pressure and body weight: the Chin‐Shan community cardiovascular cohort study. Atherosclerosis 2002; 161: 409–415. OS
  • The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995; 273: 199–208. RT
  • Grodstein F., Manson J. E., Sampfer M. J. Postmenopausal hormone use and secondary prevention of coronary events in the nurses health study, a prospective, observational study. Ann Intern Med 2001; 135: 1–8. OS
  • Falkenborn M., Persson I., Terent A., Adami H. O., Lithell H., Bergstrom R. Hormone replacement therapy and the risk of stroke, follow‐up of a population‐based cohort in Sweden. Arch Intern Med 1993; 153: 1201–1209. OS
  • Finucane F. F., Madans J. H., Bush T. L., Wolf P. H., Kleinman J. C. Decreased risk of stroke among postmenopausal hormone users, results from a national cohort. Arch Intern Med 1993; 153: 73–79. OS
  • Scuteri A., Bos A. J. G., Brant L. J., Talbot L., Lakatta E. G., Fleg J. L. Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 2001; 135: 229–238. OS
  • Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) research group. JAMA 1998; 280: 605–613. RT
  • Rossouw J. E., Anderson G. L., Prentice R. L., LaCroix A. Z., Kopperberg C., Stefanick M. L., Jackson R. D., Beresford S. A., Howard B. V., Johnson K. C., Kotchen J. M., Ockene J., Writing Group of Womefts Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womeris Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333. RT
  • Farquhar C. M., Marjoribanks J., Lethaby A., Lamberts Q., Suckling J. A., the Cochrane HT Study Group. Long term hormone therapy for perimeno‐pausal and postmenopausal women. Cochrane database of Systematic Reviews 2005, Issue 3. Art No CD004143. DOI 10.1002/1465868. CD004143.pub2. MA
  • Stramba‐Badiale M., Fox K. M., Priori S. G., Collins P., Daly C., Graham I., Jonsson B., Schenck‐Gustafsson K., Tendera M. Cardiovascular disease in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006; 27: 994–1005. GL
  • Consensus Report: National High Blood Pressure Education Program Working Group Report on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 1990; 163: 1689–1712. GL
  • Levine R. J., Ewell M. G., Hauth J. C., Curet L. B., Catalano P. M., Morris C. D., Choudhary G., Sibai B. M. Should the definition of preeclampsia include a rise in diastolic blood pressure of ⩾15 mm Hg to a level >90 mm Hg in association with proteinuria?. Am J Obstet Gynecol 2000; 183: 787–792. GL
  • Staessen J. A., Asmar R., De Buyzere M., Imai Y., Parati G., Shimada K., Stergiou G., Redon J., Verdecchia P., Participants of the 2001 Consensus Conference on Ambulatory Blood Pressure Monitoring. Task Force II: blood pressure measurement and cardiovascular outcome. Blood Press Monit 2001; 6: 355–370. GL
  • Churchill D., Perry I. J., Beevers D. G. Ambulatory blood pressure in pregnancy and fetal growth. Lancet 1997; 349: 7–10. OS
  • Penny J. A., Halligan A. W., Shennan A. H., Lambert P. C., Jones D. R., de Swiet M., Taylor D. J. Automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension?. Am J Obstet Gynecol 1998; 178: 521–526. OS
  • Perry I. J., Stewart B. A., Brockwell J., Khan M., Davies P., Beevers D. G., Luesley D. M. Recording diastolic blood pressure in pregnancy. Br Med J 1990; 301: 1198
  • Shennan A., Gupta M., Halligan A., Taylor D. J., de Swiet M. Lack of reproducibility in pregnancy of Korotkoff phase IV as measured by mercury sphygmomanometry. Lancet 1996; 347: 139–142. OS
  • Higgins J. R., de Swiet M. Blood pressure measurement and classification in pregnancy. Lancet 2001; 357: 131–135
  • Task Force Members, Oakley C., Child A., Lung B., Persbitero P., Tornos, Klein W., Garcia M. A. A., Blomstrom‐Lundqvist C., de Backer G., Dargie H., Deckers J., Flather M., Hradec J., Mazzotta G., Oto A., Parkhomenko A., Silber S., Torbicki A., Trappe H‐J., Dean V., Pourmeyrol‐Jumeau D. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24: 761–781. GL
  • Moutquin J‐M., Garner P. R., Burrows R. F., Rey E., Helewa M. E., Lange I. R., Rabkin S. W. Report of the Canadian Hypertension Society Consensus Conference: 2. Nonpharmacologic management and prevention of hypertensive disorders in pregnancy. Can Med Assoc J 1997; 157: 907–919. GL
  • Atallah A. N., Hofmeyr G. J., Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems (Cochrane Review). In: The Cochrane Library, Issue 1. Update Software, Oxford 2000, MA
  • Olsen S., Secher N. J., Tabor A., Weber T., Walker J. J., Gluud C. Randomised clinical trials offish oil supplementation in high risk pregnancies. Br J Obstet Gynaecol 2000; 107: 382–395. RT
  • Knight M., Duley L., Henderson‐Smart D. J., King J. F. Antiplatelet agents and pre‐eclampsia (Cochrane Review). The Cochrane Library. 2000, Issue 1. Oxford, Update Software, MA
  • Gilbert J. S., Cox L. A., Mitchell G., Nijland M. J. Nutrient‐restricted fetus and the cardio‐renal connection in hypertensive offspring. Expert Rev Cardiovasc Ther 2006; 4: 227–237. RV
  • Sibai B. M., Mabie W. C., Shamsa F., Vilnar M. A., Anderson G. D. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol 1990; 162: 960–967. RT
  • Gruppo di Studio Ipertensione in Gravidanza. Nifedipine versus expectant management in mild to moderate hypertension in pregnancy. Br J Obstet Gynaecol 1998; 105: 718–722. RT
  • De Swiet M. Maternal blood pressure and birthweight. Lancet 2000; 355: 81–82. RV
  • von Dadelszen P., Ornstein M. P., Bull S. B., Logan A. G., Koren G., Magee L. A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta‐analysis. Lancet 2000; 355: 87–92. MA
  • Magee L. A., Ornstein M. P., von Dadelszen P. Management of hypertension in pregnancy. Br Med J 1999; 318: 1332–1336. GL
  • Coppage K. H., Sibai B. M. Treatment of hypertensive complications in pregnancy. Current Pharm Design 2005; 11: 749–757. RV
  • Lydakis C., Lip G. Y., Beevers M., Beevers D. G. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertension 1999; 12: 541–547. OS
  • The Magpie Trial Collaborative Group. Do women with pre‐eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo‐controlled trial. Lancet 2002; 359: 1877–1890. RT
  • Paradisi G., Biaggi A., Savone R., Ianniello F., Tomei C., Caforio L., Caruso A. Cardiovascular risk factors in healthy women with previous gestational hypertension. J Clin Endocrinol Metab 2006; 91: 1233–1238. OS
  • Wilson B. J., Watson M. S., Prescott G. J., Sunderland S., Campbell D. M., Hannaford P., Smith W. C. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study. Br MedJ 2003; 326: 845–851. OS
  • Lakka H. M., Laaksonen D. E., Lakka T. A., Niskanen L. K., Kumpusalo E., Tuomilehto J., Salonen J. T. The metabolic syndrome and total and cardiovascular disease mortality in middle‐aged men. JAMA 2002; 288: 2709–2716. OS
  • Girman C. J., Rhodes T., Mercuri M., Pyorala K., Kjekshus J., Pedersen T. R., Beere P. A., Gotto A. M., Clearfield M., 4S Group the AFCAPS/TexCAPS Research Group. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136–141. OS
  • Dekker J. M., Girman C., Rhodes T., Nijpels G., Stehouwer C. D., Bouter L. M., Heine R. J. Metabolic syndrome and 10‐year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666–673. OS
  • Resnick H. E., Jones K., Ruotolo G., Jain A. K., Henderson J., Lu W., Howard B. V. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care 2003; 26: 861–867. OS
  • Schmidt M. I., Duncan B. B., Bang H., Pankow J. S., Ballantyne C. M., Golden S. H., Folsom A. R., Chambless L. E. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in Communities study. Diabetes Care 2005; 28: 2013–2018. OS
  • Mule G., Nardi E., Cottone S., Cusimano P., Volpe V., Piazza G., Mongiovi R., Mezzatesta G., Andronico G., Cerasola G. Influence of metabolic syndrome on hypertension‐related target organ damage. J Intern Med 2005; 257: 503–513. OS
  • Leoncini G., Ratto E., Viazzi F., Vaccaro V., Parodi D., Parodi A., Falqui V., Tomolillo C., Deferrari G., Pontremoli R. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med 2005; 257: 454–460. OS
  • Cuspidi C., Meani S., Fusi V., Severgnini B., Valerio C., Catini E., Leonetti G., Magrini F., Zanchetti A. Metabolic syndrome and target organ damage in untreated essential hypertensives. JHypertens 2004; 22: 1991–1998. OS
  • Schillaci G., Pirro M., Vaudo G., Mannarino M. R., Savarese G., Pucci G., Franklin S. S., Mannarino E. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1978–1982. OS
  • de Simone G., Palmieri V., Bella J. N., Celentano A., Hong Y., Oberman A., Kitzman D. W., Hopkins P. N., Arnett D. K., Devereux R. B. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 2002; 20: 323–331. OS
  • Schillaci G., Pirro M., Pucci G., Mannarino M. R., Gemelli F., Siepi D., Vaudo G., Mannarino E. Different impact of the metabolic syndrome on left ventricular structure and function in hypertensive men and women. Hypertension 2006; 47: 881–886. OS
  • Cuspidi C., Meani S., Fusi V., Valerio C., Catini E., Sala C., Sampieri L., Magrini F., Zanchetti A. Prevalence and correlates of left atrial enlargement in essential hypertension: role of ventricular geometry and the metabolic syndrome: the Evaluation of Target Organ Damage in Hypertension study. J Hypertens 2005; 23: 875–882. OS
  • Kawamoto R., Tomita H., Oka Y., Kodama A., Kamitani A. Metabolic syndrome amplifies the LDL‐cholesterol associated increases in carotid atherosclerosis. Intern Med 2005; 44: 1232–1238. OS
  • Cuspidi C., Meani S., Valerio C., Fusi V., Catini E., Sala C., Zanchetti A. Ambulatory blood pressure, target organ damage and left atrial size in never‐treated essential hypertensive individuals. J Hypertens 2005; 23: 1589–1595. OS
  • Pepys M. B., Hirschfield G. M. C‐reactive protein: a critical update. J Clin Invest 2003; 111: 1805–1812. RV
  • Nesto R. C‐reactive protein its role in inflammation Type 2 diabetes cardiovascular disease the effects of insulin‐sensitizing treatment with thiazolidinediones. Diabet Med 2004; 21: 810–817. RV
  • Mancia G., Bousquet P., Elghozi J. L., Esler M., Grassi G., Julius S., Reid J., Van Zwieten P. A. The sympathetic nervous system and the metabolic syndrome. J Hypertens 2007, in press. RV
  • Clinical guidelines on the identification evaluation treatment of overweight obesity in adults‐the evidence report. National Institutes of Health. ObesRes 1998; 2((Suppl 6))51S–209S. GL
  • Krauss R. M., Eckel R. H., Howard B., Appel L. J., Daniels S. R., Deckelbaum R. J., Erdman J. W., Jr., Kris‐Etherton P., Goldberg I. J., Kotchen T. A., Lichtenstein A. H., Mitch W. E., Mullis R., Robinson K., Wylie‐Rosett J., St Jeor S., Suttie J., Tribble D. L., Bazzarre. TL AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000; 102: 2284–2299. GL
  • Thompson P. D., Buchner D., Pina I. L., Balady G. J., Williams M. A., Marcus B. H., Berra K., Blair S. N., Costa F., Franklin B., Fletcher G. F., Gordon N. F., Pate R. R., Rodriguez B. L., Yancey A. K., Wenger N. K., American Heart Association Council on Clinical Cardiology Subcommittee on Exercise Rehabilitation Prevention American Heart Association Council on Nutrition Physical Activity Metabolism Subcommittee on Physical Activity. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the American Heart Association Council on Clinical Cardiology (Subcommittee on Nutrition, Physical Activity and Metabolism (Subcommittee on Physical Activity). Circulation 2003; 107: 3109–3116. GL
  • Knowler W. C., Barrett‐Connor E., Fowler S. E., Hamman R. F., Lachin J. M., Walker E. A., Nathan D. M., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403. RT
  • Tuomilehto J., Lindstrom J., Eriksson J. G., Valle T. T., Hamalainen H., Ilanne‐Parikka P., Keinanen‐Kiukaanniemi S., Laakso M., Louheranta A., Rastas M., Salminen V., Uusitupa M., Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350. RT
  • Orchard T. J., Temprosa M., Goldberg R., Haffner S., Ratner R., Marcovina S., Fowler S., Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005; 142: 611–619. RT
  • Pischon T., Sharma A. M. Use of beta‐blockers in obesity hypertension: potential role of weight gain. Obes Rev 2001; 2: 275–280. RV
  • Jacob S., Rett K., Henriksen E. J. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta‐blocking agents?. Am J Hypertens 1998; 11: 1258–1265. RV
  • Poole‐Wilson P. A., Swedberg K., Cleland J. G., Di Lenarda A., Hanrath P., Komajda M., Lubsen J., Lutiger B., Metra M., Remme W. J., Torp‐Pedersen C., Scherhag A., Skene A., Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003; 362: 7–13. RT
  • Abuissa H., Jones P. G., Marso S. P., O'Keefe J. H., Jr. Angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta‐analysis of randomized clinical trials. J Am Coll Cardiol 2005; 46: 821–826. MA
  • Rocchini A. P. Obesity hypertension salt sensitivity insulin resistance. Nutr Metab Cardiovasc Dis 2000; 10: 287–294. RV
  • Bakris G., Molitch M., Hewkin A., Kipnes M., Sarafidis P., Fakouhi K., Bacher P., Sowers J., STAR Investigators. Differences in glucose tolerance between fixed‐dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592–2597
  • Zillich A. J., Garg J., Basu S., Bakris G. L., Carter B. L. Thiazide diuretics potassium the development of diabetes: a quantitative review. Hypertension 2006; 48: 219–224. MA
  • Van de Laar F. A., Lucassen P. L., Akkermans R. P., Van de Lisdonk E. H., De Grauw W. J. Alpha‐glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose. Cochrane Database SystRev 2006; 4: CD005061. RV
  • Kurtz T. W., Pravenec M. Antidiabetic mechanisms of angiotensin‐converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin‐angiotensin system. J Hypertens 2004; 22: 2253–2261. RV
  • Schupp M., Janke J., Clasen R., Unger T., Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator‐activated receptor‐gamma activity. Circulation 2004; 109: 2054–2057
  • DREAM (Diabetes REduction Assessment with ramipril rosiglitazone Medication) Trial Investigators; Gerstein HC, Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., Hanefeld M., Hoogwerf B., Laakso M., Mohan V., Shaw J., Zinman B., Holman R. R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096–1105. RT
  • Dormandy J. A., Charbonnel B., Eckland D. J., Erdmann E., Massi‐Benedetti M., Moules I. K., Skene A. M., Tan M. H., Lefebvre P. J., Murray G. D., Standl E., Wilcox R. G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R. J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., Taton J., PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279–1289. RT
  • Sarafidis P. A., Nilsson P. M. The effects of thiazolidinediones on blood pressure levels ‐ a systematic review. Blood Press 2006; 15: 135–150. RV
  • Van Gaal L. F., Rissanen A. M., Scheen A. J., Ziegler O., Rossner S., RIO‐Europe Study Group. Effects of the cannabinoid‐1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1‐year experience from the RIO‐Europe study. Lancet 2005; 365: 1389–1397. RT
  • Despres J. P., Golay A., Sjostrom L., Rimonabant in Obesity‐Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353: 2121–2134. RT
  • Pi‐Sunyer F. X., Aronne L. J., Heshmati H. M., Devin J., Rosenstock J., RIO‐North America Study Group. Effect of rimonabant, a cannabinoid‐1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO‐North America: a randomized controlled trial. JAMA 2006; 295: 761–775. RT
  • Scheen A. J., Finer N., Hollander P., Jensen M. D., Van Gaal L. F., RIO‐Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 2006; 368: 1160–1172. RT
  • ClinicalTrials.gov.CRESCENDO: comprehensive rimonabant evaluation study of cardiovascular endopoints outcomes. December 2005: http//clinicaltrials.gov/. RT
  • Deedwania P., Barter P., Carmena R., Fruchart J. C., Grundy S. M., Haffner S., Kastelein J. J., LaRosa J. C., Schachner H., Shepherd J., Waters D. D. Reduction of low‐density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368: 919–928. RT
  • Wing R. R., Phelan S. Long‐term weight loss maintenance. Am J Clin Nutr 2005; 82((1 Suppl))222S–225S. RV
  • Cuspidi C., Macca G., Sampieri L., Michev I., Salerno M., Fusi V., Severgnini B., Meani S., Magrini F., Zanchetti A. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001; 19: 2063–2070. OS
  • Logan A. G., Perlikowski S. M., Mente A., Tisler A., Tkacova R., Niroumand M., Leung R. S., Bradley T. D. High prevalence of unrecognized sleep apnoea in drug‐resistant hypertension. J Hypertens 2001; 19: 2271–2277. OS
  • Parati G., Ongaro G., Bonsignore M. R., Glavina F., Di Rienzo M., Mancia G. Sleep apnoea and hypertension. Curr Opin Nephrol Hypertens 2002; 11: 201–214. RV
  • Narkiewicz K., Wolf J., Lopez‐Jimenez F., Somers V. K. Obstructive sleep apnea and hypertension. Curr Cardiol Rep 2005; 7: 435–440. RV
  • Baguet J. P., Narkiewicz K., Mallion J. M. Update on hypertension management: obstructive sleep apnea and hypertension. J Hypertens 2006; 24: 205–208. RV
  • Calhoun D. A. Low‐dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens 2007; 9((Suppl 1))19–24. RV
  • Saha C., Eckert G. J., Ambrosius W. T., Chun T. Y., Wagner M. A., Zhao Q., Pratt J. H. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46: 481–487. RT
  • Lane D. A., Shah S., Beevers D. G. Low‐dose spironolactone in management of resistant hypertension: a surveillance study. J Hypertens 2007; 25: 891–894. OS
  • Eide I. K., Torjesen P. A., Drolsum A., Babovic A., Lilledahl N. P. Low‐renin status in therapy‐resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22: 2217–2226. OS
  • de Leeuw P. W., Kroon A. A., Scheffers I., Tordoir J., Schmidli, Mohaupt M., Allemann Y., Jordan J., Engeli S., Liebeskind U., Luft F. C., Eckert S., Hansky B., Kieval R., Cody R., Rossing M., Irwin E., Peters T. Baroreflex hypertension therapy with a cronically implanted system: preliminary efficacy and safety results from the rheos debut‐ht study in patients with resistant hypertension. J Hypertens 2006; 24((Suppl 4))S300. (abstract)
  • Isles C. G. Malignant hypertension and hypertensive encephalophaty. Textbook of Hypertension, J. D Swales. Blackwell Scientific Publications, London 1994; 1233–1248. RV
  • Davis B. A., Crook J. E., Vestal R. E., Oates J. A. Prevalence of renovascular hypertension in patients with grade III or IV hypertensive retinopathy. NEngl J Med 1979; 301: 1273–1276. OS
  • Lip G. Y., Beevers M., Beevers G. The failure of malignant hypertension to decline: a survey of 24 years' experience in a multiracial population in England. J Hypertens 1994; 12: 1297–1305. OS
  • Giese J. Acute hypertensive vascular disease, 2: Studies on vascular reaction patterns and permeability changes by means of vital microscopy and colloidal tracer technique. Acta Pathol Microbiol Scand 1964; 62: 497–515. OS
  • Kincaid‐Smith P., McMichael J., Murphy E. A. The clinical cause and pathology of hypertension with papilloedema. Quart J Med 1958; 27: 117–154. OS
  • Isles C. G., Liu K. G., Boulton‐Jones M., Cameron H., Lever A. F., Murray G., Robertson J. W. K. Factors influencing mortality in malignant hypertension. J Hypertens 1985; 3((Suppl 3))405–407. OS
  • Lip G. Y., Beevers M., Beevers D. G. Complications and survival of 315 patients with malignant‐phase hypertension. J Hypertens 1995; 13: 915–924. OS
  • Gotto A. M., Jr. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol 2005; 96: 34F–38F. RV
  • Clearfield M. Statins and the primary prevention of cardiovascular events. Curr Atheroscler Rep 2006; 8: 390–396. RV
  • Thavendiranathan P., Bagai A., Brookhart M. A., Choudhry N. K. Primary prevention of cardiovascular diseases with statin therapy: a meta‐analysis of randomized controlled trials. Arch Intern Med 2006; 166: 2307–2313. MA
  • Gorelick P. B., Schneck M., Berglund L. F., Feinberg W., Goldstone J. Status of lipids as a risk factor for stroke. Neuroepidemiology 1997; 16: 107–115. RV
  • Heart Protection Study Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high‐risk individuals: a randomised placebo‐controlled trial. Lancet 2002; 360: 7–22. RT
  • Shepherd J., Blauw G. J., Murphy M. B., Bollen E. L., Buckley B. M., Cobbe S. M., Ford I., Gaw A., Hyland M., Jukema J. W., Kamper A. M., Macfarlane P. W., Meinders A. E., Norrie J., Packard C. J., Perry I. J., Stott D. J., Sweeney B. J., Twomey C., Westendorp R. G., PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623–1630. RT
  • Amarenco P., Bogousslavsky J., Callahan A., 3rd., Goldstein L. B., Hennerici M., Rudolph A. E., Sillesen H., Simunovic L., Szarek M., Welch K. M., Zivin J. A., Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High‐dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549–559. RT
  • The ALLHAT Officers, Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT‐LLT). JAMA 2002; 288: 2998–3007. RT
  • Sever P. S., Dahlof B., Poulter N. R., Wedel H., Beevers G., Caulfield M., Collins R., Kjeldsen S. E., Kristinsson A., McInnes G. T., Mehlsen J., Nieminen M., O'Brien E., Ostergren J., ASCOT investigators. The prevention of coronary events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo‐Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT:LLA). Lancet 2003; 361: 1149–1158. RT
  • Borghi C., Dormi A., Veronesi M., Immordino V., Ambrosioni E. Use of lipid‐lowering drugs and blood pressure control in patients with arterial hypertension. J Clin Hypertens 2002; 4: 277–285. RV
  • Kosoglou T., Statkevich P., Johnson‐Levonas A. O., Paolini J. F., Bergman A. J., Alton K. B. Ezetimibe: a review of its metabolism pharmacokinetics drug interactions. Clin Pharmacokinet 2005; 44: 467–494. RV
  • Antithrombotic Trialists' Collaboration. Collaborative meta‐analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86. MA
  • Zanchetti A., Hansson L., Dahlof B., Julius S., Menard J., Warnold I., Wedel H. Benefit and harm of low‐dose aspirin in well‐treated hypertensives at different baseline cardiovascular risk. J Hypertens 2002; 20: 2301–2307. CT
  • Diener H. C., Bogousslavsky J., Brass L. M., Cimminiello C., Csiba L., Kaste M., Leys D., Matias‐Guiu J., Rupprecht H. J. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high‐risk patients (MATCH): randomised, double‐blind, placebo‐controlled trial. Lancet 2004; 364: 331–337. RT
  • Ridker P. M., Cook N. R., Lee I. M., Gordon D., Gaziano J. M., Manson J. E., Hennekens C. H., Buring J. E. A randomized trial of low‐dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–1304. RT
  • Hayden M., Pignone M., Phillips C., Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136: 161–172. MA
  • Wald N. J., Law M. R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419. RV
  • Sanmuganathan P. S., Ghahramani P., Jackson P. R., Wallis E. J., Ramsay L. E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta‐analysis of randomised trials. Heart 2001; 85: 265–271. MA
  • Zanchetti A., Hansson L., Leonetti G., Rahn K. H., Ruilope L., Warnold I., Wedel H. Low‐dose aspirin does not interfere with the blood pressure‐lowering effects of antihypertensive therapy. J Hypertens 2002; 20: 1015–1022. RT
  • Haffner S. M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non‐diabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229–234. OS
  • Stamler J., Vaccaro O., Neaton J. D., Wentworth D. Diabetes other riskfactors 12‐yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–444. OS
  • Knowler W. C., Sartor G., Melander A., Schersten B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997; 40: 680–686. OS
  • Gress T. W., Nieto F. J., Shahar E., Wofford M. R., Brancati F. L. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342: 905–912. OS
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853. RT
  • Chiasson J. L., Josse R. G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP‐ NIDDM trial. JAMA 2003; 290: 486–494. RT
  • Gaede P., Vedel P., Larsen N., Jensen G. V., Parving H. H., Pedersen O. Multi‐factorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393. RT
  • The Diabetes Control, Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986. RT
  • Nathan D. M., Cleary P. A., Backlund J. Y., Genuth S. M., Lachin J. M., Orchard T. J., Raskin P., Zinman B., Diabetes Control Complications Trial/Epidemiology of Diabetes Interventions Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643–2653. CT
  • Balkau B., Shipley M., Jarrett R. J., Pyorala K., Pyorala M., Forhan A., Eschwege E. High blood glucose concentration is a risk factor for mortality in middle‐aged nondiabetic men. 20‐year follow‐up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998; 21: 360–367. OS
  • European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabetes Med 1999; 16: 716–730. GL
  • ADVANCE trial study group Rationale, design of the ADVANCE study: a randomised trial of blood pressure lowering, intensive glucose control in high‐risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified‐Release Controlled Evaluation. J Hypertens 2001; 19((Suppl))S21–S28. RT
  • Campos C., Segura J., Rodicio J. L. Investigations in secondary hypertension: renal disease. Hypertension, A Zanchetti, L Hansson, J. L Rodicio. McGraw Hill International, London 2001; 119–126. RV
  • Keane W. F., Eknoyan G. Proteinuria albuminuria risk assessment detection elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004–1010. GL
  • Koler H., Wandel E., Brunck B. Acanthocyturia ‐ a characteristic marker for glomerular bleeding. Kidney Int 1991; 40: 115–120. OS
  • Elliott W. J. Secondary hypertension: renovascular hypertension. Hypertension: a Companion to Braunwald's Heart Disease, W. G Blackh & Elliott, 2007; 93–105. RV, Saunders Elsevier
  • Safian R. D., Textor S. C. Renal‐artery stenosis. N Engl J Med 2001; 344: 431–442. RV
  • Krumme W., Blum U., Schwertfeger E., Fliigel P., Hollstin F., Schollmeyer P., Rump L. C. Diagnosis of renovascular disease by intra‐extrarenal Doppler scanning. Kidney Int 1996; 50: 1288–1292. OS
  • Vasbinder B. G. C., Nelemans P. J., Kessels A. G. H., Kroon A. A., De Leeuw P. W., van Engelshoven J. M. A. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta‐analysis. Ann Intern Med 2001; 135: 401–411. MA
  • Bruce G. H. Intervention for renal artery stenosis: endovascular and surgical roles. J Hypertens 2005; 23((Suppl 3))S23–S29. RV
  • Aurell M., Jensen G. Treatment of renovascular hypertension. Nephron 1997; 75: 373–383. RV
  • Plouin P. F., Chatellier G., Darne B., Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Essai Multicentrique Medicaments vs Angioplastie (EMMA) Study Group. Hypertension 1998; 31: 823–829. RT
  • Webster J., Marshall F., Abdalla M., Dominiczak A., Edwards R., Isles C. G., Loose H., Main J., Padfield P., Russell I. T., Walker B., Watson M., Wilkinson R. Randomised comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. Scottish and Newcastle Renal Artery Stenosis Collaborative Group. J Hum Hypertens 1998; 12: 329–335. OS
  • van Jaarsveld B. C., Krijnen P., Pieterman H., Derkx F. H., Deinum J., Postma C. T., Dees A., Woittiez A. J., Bartelink A. K., Man in ’tVeld A. J., Schalekamp M. A. The effect of balloon angioplasty on hypertension in atherosclerotic renal‐artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med 2000; 342: 1007–1014. OS
  • Nordmann A. J., Woo K., Parkes R., Logan A. G. Balloon angioplasty or medical therapy for hypertensive patients with atherosclerotic renal artery stenosis? A meta‐analysis of randomized controlled trials. Am J Med 2003; 114: 44–50. MA
  • Reisch N., Peczkowska M., Januszewicz A., Neumann H. P. Pheochromocytoma: presentation diagnosis treatment. J Hypertens 2006; 24: 2331–2339. RV
  • Sawka A. M., Jaeschke R., Singh R. J., Young W. F., Jr. A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24‐hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 2003; 88: 553–558. OS
  • Bravo E. L. Evolving concepts in the pathophysiology diagnosis treatment of pheochromocytoma. Endocrine Rev 1994; 15: 356–368. RV
  • Goldstein D. S., Eisenhofer G., Flynn J. A., Wand G., Pacak K. Diagnosis and localization of pheochromocytoma. Hypertension 2004; 43: 907–910. RV
  • Sjoberg R. J., Simcic K. J., Kidd G. S. The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 1992; 152: 1193–1197. RV
  • Ilias I., Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 2004; 89: 479–491. RV
  • Gimm O., Koch C. A., Januszewicz A., Opocher G., Neumann H. P. The genetic basis of pheochromocytoma. Front Horm Res 2004; 31: 45–60. RV
  • Rossi G. P., Bernini G., Caliumi C., Desideri G., Fabris B., Ferri C., Ganzaroli C., Giacchetti G., Letizia C., Maccario M., Mallamaci F., Mannelli M., Mattarello M. J., Moretti A., Palumbo G., Parenti G., Porteri E., Semplicini A., Rizzoni D., Rossi E., Boscaro M., Pessina A. C., Mantero F., PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293–2300. OS
  • Stowasser M., Gordon R. D., Gunasekera T. G., Cowley D. C., Ward G., Archibald C., Smithers B. M. High rate of detection of primary aldosteronism, including surgically treatable forms, after ‘non‐selective’ screening of hypertensive patients. J Hypertens 2003; 21: 2149–2157. OS
  • Bravo E. L., Tarazi R. C., Dustan H. P., Fouad F. M., Textor S. C., Gifford R. W., Vidt D. G. The changing clinical spectrum of primary aldosteronism. Am J Med 1983; 74: 641–651. RV
  • Ganguly A. Primary aldosteronism. NEngl J Med 1998; 339: 1828–1834. RV
  • Kaplan N. M. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004; 22: 863–869. RV
  • Gordon R. D., Stowasser M., Tunny T. J., Klemm S. A., Rutherford J. C. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315–318. OS
  • Lins P. E., Adamson U. Plasma aldosterone‐plasma renin activity ratio. A simple test to identify patients with primary aldosteronism. Acta Endocrinol 1986; 113: 564–569. OS
  • Pimenta E., Calhoun D. A. Primary aldosteronism: diagnosis treatment. J Clin Hypertens 2006; 8: 887–893. RV
  • Phillips J. L., Walther M. M., Pezzullo J. C., Rayford W., Choyke P. L., Berman A. A., Linehan W. M., Doppman J. L., Gill J. R., Jr. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone‐producing adrenal adenoma. J Clin Endocrinol Metab 2000; 85: 4526–4533. OS
  • Bravo E. L. Secondary Hypertension: Mineralocorticoid excess states. Hypertension: A Companion to Braunwald's Heart diseases, H. R Black, W. J Elliott. Saunders‐Elsevier, Amsterdam 2007; 106–118. RV
  • Krum H., Gilbert R. E. Novel therapies blocking the renin‐angiotensin‐aldosterone system in the management of hypertension and related disorders. J Hypertens 2007; 25: 25–35. RV
  • Newell‐Price J., Bertagna X., Grossman A. B., Nieman L. K. Cushing's syndrome. Lancet 2006; 367: 1605–1617. RV
  • Findling J. W., Raff H. Cushing's Syndrome: important issues in diagnosis management. J Clin Endocrinol Metab 2006; 91: 3746–3753. RV
  • Strollo P. J., Jr., Rogers R. M. Obstructive sleep apnea. N Engl J Med 1996; 334: 99–104. RV
  • Lavie P., Herer P., Hoffstein V. Obstructive sleep apnoea syndrome as a risk factor for hypertension: population study. Br Med J 2000; 320: 479–482. OS
  • Grote L., Ploch T., Heitmann J., Knaack L., Penzel T., Peter J. H. Sleep‐related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med 1999; 160: 1875–1882. OS
  • Parati G., Bilo G., Lombardi C., Mancia G. Secondary hypertension: Sleep Apnea. Hypertension: A companion to Braunwald's Heart diseases, H. R Black, W. J Elliott. Saunders‐Elsevier, Amsterdam 2007; 134–143. RV
  • Australian National Health Medical Research Council Dietary Salt Study Management Committee. Fall in blood pressure with modest reduction in dietary salt intake in mild hypertension. Lancet 1989; i: 399–402. RT
  • Port K., Palm K., Viigimaa M. Daily usage and efficiency of remote home monitoring in hypertensive patients over a one‐year period. J Telemed Telecare 2005; 11((Suppl 1))34–36. OS
  • Kearney P. M., Whelton M., Reynolds K., Whelton P. K., He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11–19. RV
  • Burt V. L., Cutler J. A., Higgins M., Horan M. J., Labarthe D., Whelton P., Brown C., Roccella E. J. Trends in the prevalence awareness treatment control of hypertension in the adult US population. Data from the Health Examination Surveys 1960 to 1991. Hypertension 1995; 26: 60–69. OS
  • Amar J., Chamontin B., Genes N., Cantet C., Salvador M., Cambou J. P. Why is hypertension so frequently uncontrolled in secondary prevention?. J Hypertens 2003; 21: 1199–1205. OS
  • Mancia G., Ambrosioni E., Agabiti‐Rosei E., Leonetti G., Trimarco B., Volpe M. Blood pressure control and risk of stroke in untreated and treated hypertensive patients screened from clinical practice: results of the ForLife study. J Hypertens 2005; 23: 1575–1581. OS

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.